WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS
- Fluoroquinolones, including CIPRO ®, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5.1)], including:
- Tendinitis and tendon rupture [see Warnings and Precautions (5.2)].
- Peripheral neuropathy [see Warnings and Precautions (5.3)].
- Central nervous system effects [see Warnings and Precautions (5.4)]. Discontinue CIPRO immediately and avoid the use of fluoroquinolones, including CIPRO, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5.1)].
- Fluoroquinolones, including CIPRO, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid CIPRO in patients with known history of myasthenia gravis. [see Warnings and Precautions (5.5)].
- Because fluoroquinolones, including CIPRO, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.16)], reserve CIPRO for use in patients who have no alternative treatment options for the following indications:
- Acute exacerbation of chronic bronchitis [see Indications and Usage (1.10)].
- Acute uncomplicated cystitis [see Indications and Usage (1.11)].
- Acute sinusitis [see Indications and Usage (1.12)]. WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS See full prescribing information for complete boxed warning.
- Fluoroquinolones, including CIPRO ®, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together (5.1), including:
- Tendinitis and tendon rupture (5.2)
- Peripheral neuropathy (5.3)
- Central nervous system effects (5.4) Discontinue CIPRO immediately and avoid the use of fluoroquinolones, including CIPRO, in patients who experience any of these serious adverse reactions (5.1)
- Fluoroquinolones, including CIPRO, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid CIPRO in patients with known history of myasthenia gravis. (5.5)
- Because fluoroquinolones, including CIPRO, have been associated with serious adverse reactions (5.1-5.16), reserve CIPRO for use in patients who have no alternative treatment options for the following indications:
- Acute exacerbation of chronic bronchitis (1.10)
- Acute uncomplicated cystitis (1.11) Acute sinusitis (1.12)
Use: Labeled indications
- Skin and Skin Structure Infections
- Bone and Joint Infections
- Complicated Intra-Abdominal Infections
- Infectious Diarrhea
- Typhoid Fever (Enteric Fever)
- Uncomplicated Cervical and Urethral Gonorrhea
- Inhalational Anthrax post-exposure in adult and pediatric patients
- Plague in adult and pediatric patients
Full indications and usage US FDA label
1 INDICATIONS AND USAGE CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated:
- Skin and Skin Structure Infections (1.1)
- Bone and Joint Infections (1.2)
- Complicated Intra-Abdominal Infections (1.3)
- Infectious Diarrhea (1.4)
- Typhoid Fever (Enteric Fever) (1.5)
- Uncomplicated Cervical and Urethral Gonorrhea (1.6)
- Inhalational Anthrax post-exposure in adult and pediatric patients (1.7)
- Plague in adult and pediatric patients (1.8)
- Chronic Bacterial Prostatitis (1.9)
- Lower Respiratory Tract Infections (1.10)
- Acute Exacerbation of Chronic Bronchitis
- Urinary Tract Infections (1.11)
- Urinary Tract Infections (UTI)
- Acute Uncomplicated Cystitis
- Complicated UTI and Pyelonephritis in Pediatric Patients
- Acute Sinusitis (1.12) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.13) 1.1 Skin and Skin Structure Infections CIPRO is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.2 Bone and Joint Infections CIPRO is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.3 Complicated Intra-Abdominal Infections CIPRO is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.4 Infectious Diarrhea CIPRO is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii †, Shigella dysenteriae, Shigella flexneri or Shigella sonnei † when antibacterial therapy is indicated. † Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.5 Typhoid Fever (Enteric Fever) CIPRO is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.6 Uncomplicated Cervical and Urethral Gonorrhea CIPRO is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see Warnings and Precautions (5.17)]. 1.7 Inhalational Anthrax (Post-Exposure) CIPRO is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001 [see Clinical Studies (14.2)]. 1.8 Plague CIPRO is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies (14.3)]. 1.9 Chronic Bacterial Prostatitis CIPRO is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.10 Lower Respiratory Tract Infections CIPRO is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. CIPRO is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. CIPRO is indicated for the treatment of acute exacerbations of chronic bronchitis (AECB) caused by Moraxella catarrhalis. Because fluoroquinolones, including CIPRO, have been associated with serious adverse reactions [see Warnings and Precautions (5.1–5.16)] and for some patients AECB is self-limiting, reserve CIPRO for treatment of AECB in patients who have no alternative treatment options. 1.11 Urinary Tract Infections Urinary Tract Infections in Adults CIPRO is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis CIPRO is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. Because fluoroquinolones, including CIPRO, have been associated with serious adverse reactions [see Warnings and Precautions (5 .1-5.16)] and for some patients acute uncomplicated cystitis is self-limiting, reserve CIPRO for treatment of acute uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infection and Pyelonephritis in Pediatric Patients CIPRO is indicated in pediatric patients aged one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see Use in Specific Populations (8.4)]. Although effective in clinical trials, CIPRO is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to controls, including reactions related to joints and/or surrounding tissues. CIPRO, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see Warnings and Precautions (5.13), Adverse Reactions (6.1), Use in Specific Populations (8.4) and Nonclinical Toxicology (13.2)]. 1.12 Acute Sinusitis CIPRO is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. Because fluoroquinolones, including CIPRO, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.16)] and for some patients acute sinusitis is self-limiting, reserve CIPRO for treatment of acute sinusitis in patients who have no alternative treatment options. 1.13 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with CIPRO may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.
Contraindications
- Hypersensitivity to ciprofloxacin, any quinolone, or product components
- Concomitant tizanidine
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS • Known hypersensitivity to CIPRO or other quinolones (4.1, 5.6, 5.7) • Concomitant administration with tizanidine (4.2) 4.1 Hypersensitivity CIPRO is contraindicated in persons with a history of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials, or any of the product components [see Warnings and Precautions (5.7)]. 4.2 Tizanidine Concomitant administration with tizanidine is contraindicated [see Drug Interactions (7)].
Dosing: Adult
- Urinary tract infection: 250 to 500 mg orally every 12 hours for 7 to 14 days (acute uncomplicated cystitis: 250 mg every 12 hours for 3 days)
- Skin, bone and joint, lower respiratory tract infection: 500 to 750 mg every 12 hours
- Complicated intra-abdominal infection: 500 mg every 12 hours for 7 to 14 days
- CIPRO Tablets and Oral Suspension should be administered orally as described in the appropriate Dosage Guidelines tables. Adult Dosage Guidelines Infection Dose Frequency Duration Skin and Skin Structure 500 -750 mg every 12 hours 7 to 14 days Bone and Joint 500-750 mg every 12 hours 4 to 8 weeks Complicated Intra-Abdominal 500 mg every 12 hours 7 to 14 days Infectious Diarrhea 500 mg every 12 hours 5 to 7 days Typhoid Fever 500 mg every 12 hours 10 days Uncomplicated Gonorrhea 250 mg single dose single dose Inhalational anthrax (post-exposure) 500 mg every 12 hours 60 days Plague 500–750 mg every 12 hours 14 days Chronic Bacterial Prostatitis 500 mg every 12 hours 28 days Lower Respiratory Tract 500 -750 mg every 12 hours 7 to 14 days Urinary Tract 250-500 mg every 12 hours 7 to 14 days Acute Uncomplicated Cystitis 250 mg every 12 hours 3 days Acute Sinusitis 500 mg every 12 hours 10 days • Adults with creatinine clearance 30–50 mL/min 250–500 mg q 12 h (2.3)
- • Adults with creatinine clearance 5–29 mL/min 250–500 mg q 18 h (2.3)
- • Patients on hemodialysis or peritoneal dialysis 250–500 mg q 24 h (after dialysis) (2.3)
- Pediatric Oral Dosage Guidelines Infection Dose Frequency Duration Complicated UTI and Pyelonephritis (1 to 17 years of age) 10–20 mg/kg (maximum 750 mg per dose) Every 12 hours 10–21 days Inhalational Anthrax (Post-Exposure) 15 mg/kg (maximum 500 mg per …
2.1 Dosage in Adults
2.1 Dosage in Adults The determination of dosage and duration for any particular patient must take into consideration the severity and nature of the infection, the susceptibility of the causative microorganism, the integrity of the patient’s host-defense mechanisms, and the status of renal and hepatic function. CIPRO Tablets or CIPRO for Oral Suspension may be administered to adult patients when clinically indicated at the discretion of the physician.
Administer CIPRO for Oral Suspension using the co-packaged graduated spoon [see Dosage and Administration (2.7)]. Table 1: Adult Dosage Guidelines Infection Dose Frequency Usual Durations Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms of infection have disappeared, except for inhalational anthrax (post-exposure).
Skin and Skin Structure 500–750 mg every 12 hours 7 to 14 days Bone and Joint 500–750 mg every 12 hours 4 to 8 weeks Complicated Intra–Abdominal Used in conjunction with metronidazole. 500 mg every 12 hours 7 to 14 days Infectious Diarrhea 500 mg every 12 hours 5 to 7 days Typhoid Fever 500 mg every 12 hours 10 days Uncomplicated Urethral and Cervical Gonococcal Infections 250 mg single dose single dose Inhalational anthrax (post-exposure) Begin drug administration as soon as possible after suspected or confirmed exposure. 500 mg every 12 hours 60 days Plague 500–750 mg every 12 hours 14 days Chronic Bacterial Prostatitis 500 mg every 12 hours 28 days Lower Respiratory Tract Infections 500–750 mg every 12 hours 7 to 14 days Urinary Tract Infections 250–500 mg every 12 hours 7 to 14 days Acute Uncomplicated Cystitis 250 mg every 12 hours 3 days Acute Sinusitis 500 mg every 12 hours 10 days Conversion of IV to Oral Dosing in Adults Patients whose therapy is started with CIPRO IV may be switched to CIPRO Tablets or Oral Suspension when clinically indicated at the discretion of the physician (Table 2) [see Clinical Pharmacology (12.3)]. Table 2: Equivalent AUC Dosing Regimens CIPRO Oral Dosage Equivalent CIPRO IV Dosage 250 mg Tablet every 12 hours 200 mg intravenous every 12 hours 500 mg Tablet every 12 hours 400 mg intravenous every 12 hours 750 mg Tablet every 12 hours 400 mg intravenous every 8 hours
2.2 Dosage in Pediatric Patients
2.2 Dosage in Pediatric Patients Dosing and initial route of therapy (that is, IV or oral) for cUTI or pyelonephritis should be determined by the severity of the infection. CIPRO should be administered as described in Table 3. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon [see Dosage and Administration (2.7)].
Table 3: Pediatric Dosage Guidelines Infection Dose Frequency Total Duration Complicated Urinary Tract or Pyelonephritis (patients from 1 to 17 years of age) 10 mg/kg to 20 mg/kg (maximum 750 mg per dose; not to be exceeded even in patients weighing more than 51 kg) Every 12 hours 10–21 days 1 Inhalational Anthrax (Post-Exposure) 2 15 mg/kg (maximum 500 mg per dose) Every 12 hours 60 days Plague 2,3 15 mg/kg (maximum 500 mg per dose) Every 8 to 12 hours 14 days 1 The total duration of therapy for cUTI and pyelonephritis in the clinical trial was determined by the physician. The mean duration of treatment was 11 days (range 10 to 21 days). 2 Begin drug administration as soon as possible after suspected or confirmed exposure. 3 Begin drug administration as soon as possible after suspected or confirmed exposure to Y. pestis.
2.3 Dosage Modifications in Patients with Renal Impairment
2.3 Dosage Modifications in Patients with Renal Impairment Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment.
Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. Dosage guidelines for use in patients with renal impairment are shown in Table 4. Table 4: Recommended Starting and Maintenance Doses for Adult Patients with Impaired Renal Function Creatinine Clearance (mL/min) Dose > 50 See Usual Dosage. 30–50 250–500 mg every 12 hours 5–29 250–500 mg every 18 hours Patients on hemodialysis or Peritoneal dialysis 250–500 mg every 24 hours (after dialysis) When only the serum creatinine concentration is known, the following formulas may be used to estimate creatinine clearance: Men - Creatinine clearance (mL/min) = Weight (kg) x (140–age) 72 x serum creatinine (mg/dL) Women - 0.85 x the value calculated for men.
The serum creatinine should represent a steady state of renal function. In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patients should be carefully monitored. Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of cUTI and pyelonephritis.
No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (that is, creatinine clearance of < 50 mL/min/1.73 m²).
2.4 Important Administration Instructions With Multivalent Cations
2.4 Important Administration Instructions With Multivalent Cations Administer CIPRO at least 2 hours before or 6 hours after magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate) or sucralfate; Videx ® (didanosine) chewable/buffered tablets or pediatric powder for oral solution; other highly buffered drugs; or other products containing calcium, iron or zinc. With Dairy Products Concomitant administration of CIPRO with dairy products (like milk or yogurt) or calcium-fortified juices alone should be avoided since decreased absorption is possible; however, CIPRO may be taken with a meal that contains these products.
Hydration of Patients Receiving CIPRO Assure adequate hydration of patients receiving CIPRO to prevent the formation of highly concentrated urine. Crystalluria has been reported with quinolones. Instruct the patient of the appropriate CIPRO administration [see Patient Counseling Information (17)]. Missed Doses If a dose is missed, it should be taken anytime but not later than 6 hours prior to the next scheduled dose.
If less than 6 hours remain before the next dose, the missed dose should not be taken and treatment should be continued as prescribed with the next scheduled dose. Double doses should not be taken to compensate for a missed dose. Splitting CIPRO Tablets CIPRO Tablets, 250 mg and 500 mg are functionally scored tablets which can be split into one-half at the scored line to provide a 125 mg and 250 mg strength, respectively.
2.5 Directions for Reconstitution
2.5 Directions for Reconstitution of the CIPRO Microcapsules for Oral Suspension CIPRO Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. CIPRO oral suspension is composed of two components (microcapsules and diluent) that must be combined prior to dispensing.
Table 5: Appropriate Dosing Volumes of the Reconstituted Oral Suspensions Dose 5% (250 mg/5 mL) 10% (500 mg/5 mL) 250 mg 5 mL 2.5 mL 500 mg 10 mL 5 mL 750 mg 15 mL 7.5 mL Preparation of the suspension: Step1 The small bottle contains the microcapsules, the large bottle contains the diluent. Step 2 Open both bottles. Child-proof cap: Press down according to instructions on the cap while turning to the left.
Step 3 Pour the microcapsules completely into the larger bottle of diluent. Do not add water to the suspension. Step 4 Remove the top layer of the diluent bottle label (to reveal the CIPRO Oral Suspension label). Close the large bottle completely according to the directions on the cap and shake vigorously for about 15 seconds.
The suspension is ready for use. Step 5: Write the expiration date of the re-constituted oral suspension on the bottle label. Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing. No additions should be made to the mixed final ciprofloxacin suspension. CIPRO Oral Suspension should not be administered through feeding or NG (nasogastric) tubes due to its physical characteristics.
Step 1 Step 2 Step 3 Step 4
2.6 Administration Instructions
2.6 Administration Instructions for CIPRO for Oral Suspension After Reconstitution
- Shake CIPRO Oral Suspension vigorously each time before use for approximately 15 seconds.
- Administer CIPRO Oral Suspension using the co-packaged graduated teaspoon provided for the patient (see Figure 1) Figure 1: Co-packaged 5 mL graduated teaspoon The Co-packaged graduated teaspoon (5mL) is provided, with markings for 1/2 (2.5 mL) and 1/1 (5 mL)
- After use, clean the graduated teaspoon under running water with dish detergent and dry thoroughly.
- Do Not chew the microcapsules in the CIPRO Oral Suspension, instead swallow them whole.
- Water may be taken afterwards.
- Reclose the bottle properly after each use according to instructions on the cap.
- After treatment has been completed, CIPRO Oral Suspension should not be reused. gradated spoon
2.7 Dosing
2.7 Dosing of CIPRO for Oral Suspension using the Co-Packaged Spoon in Adults and Pediatric Patients Table 6: 5% Cipro for Oral Suspension: 250 mg ciprofloxacin per 5 mL after reconstitution Infection Body weight (kg) Dose by Measuring Spoonful(s) using Co-Packed Spoon* (teaspoonful (s) (volume (mL)) Dose Strength (mg) Complicated Urinary Tract or Pyelonephritis (patients from 1 to 17 years of age) 1 and Plague 2 9 kg to 12 kg ½ teaspoonful (2.5 mL) 125 mg 13 kg to 18 kg 1 teaspoonful (5 mL) 250 mg 19 kg to 24 kg 1 to 1 ½ teaspoonful(s) (5 mL to 7.5 mL) 250 mg to 375 mg 25 kg to 31 kg 1 ½ to 2 teaspoonfuls (7.5 mL to 10 mL) 375 mg to 500 mg 32 kg to 37 kg 1 ½ to 2 ½ teaspoonfuls (7.5 mL to 12.5 mL) 375 mg to 625 mg 38 kg or more 2 to 3 teaspoonfuls (10 mL to 15 mL) 500 mg to 750 mg Inhalational Anthrax (Post-Exposure) 3 9 kg to 12 kg ½ teaspoonful (2.5 mL) 125 mg 13 kg to 18 kg 1 teaspoonful (5 mL) 250 mg 19 kg to 24 kg 1 to 1 ½ teaspoonful(s) (5 mL to 7.5 mL) 250 mg to 375 mg 25 kg or more 2 teaspoonfuls (10 mL) 500 mg * A graduated teaspoon (5mL) with markings 1/2 (2.5) mL and 1/1 (5 mL) is provided for the patient. 1 Administer every 12 hours for 10-21 days [see Dosage and Administration (2.2)] 2 Administer every 8-12 hours for 10-21 days for Pediatric patients [see Dosage and Administration (2.2)]; for adults administer every 12 hours for 14 days [see Dosage and Administration (2.1)] 3 Administer every 12 hours for 60 days [see Dosage and Administration (2.1 and 2.2)] Table 7: 10% Oral Suspension: 500 mg ciprofloxacin per 5 mL after reconstitution (not appropriate for children weighing less than 13 kg) Infection Body weight (kg) Dose by Measuring Spoonful(s) using Co-Packed Spoon* (teaspoonful (s) (volume (mL)) Dose Strength (mg) Complicated Urinary Tract or Pyelonephritis (patients from 1 to 17 years of age) 1 and Plague 2 13 kg to 24 kg ½ teaspoonful (2.5 mL) 250 mg 25 kg ½ to 1 teaspoonful (2.5 mL to 5 mL) 250 mg to 500 mg 26 kg to 37 kg 1 teaspoonful (5 mL) 500 mg 38 kg or more 1 to 1½ teaspoonful(s) (5 mL to 7.5 mL) 500 mg to maximum dose of 750 mg Inhalational Anthrax (Post-Exposure) 3 13 kg to 24 kg ½ teaspoonful (2.5 mL) 250 mg 25 kg or more 1 teaspoonful (5 mL) 500 mg * A graduated teaspoon (5mL) with markings 1/2 (2.5) mL and 1/1 (5 mL) is provided for the patient. 1 Administer every 12 hours for 10-21 days [see Dosage and Administration (2.2)] 2 Administer every 8-12 hours for 10-21 days for Pediatric patients [see Dosage and Administration (2.2)]; for adults administer every 12 hours for 14 days [see Dosage and Administration (2.1)] 3 Administer every 12 hours for 60 days [see Dosage and Administration (2.1 and 2.2)]
Dosing: Altered kidney function
Ciprofloxacin is partly cleared by the liver and gut, so kidney impairment changes its levels less than for many antibiotics. The US labels still lower the dose at creatinine clearance (CrCl) 50 mL/min or less (oral) or below 30 mL/min (intravenous, IV) and dose after dialysis. Oral and IV doses differ; do not transpose oral mg values to IV.
Kidney function measure: Label uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault).
Show full dosing details
- CrCl ≥60 mL/min
- Usual dosing (label: CrCl >50).
- CrCl 30–59 mL/min
- Oral: CrCl >50, usual dosing; CrCl 30–50, 250 to 500 mg every 12 hours (label). IV: CrCl >30, usual dose (IV label).
- CrCl 15–29 mL/min
- Oral: CrCl 5–29, 250 to 500 mg every 18 hours (label); severe infection: a 750 mg unit dose may be given at these intervals with careful monitoring. IV: CrCl 5–29, 200 to 400 mg every 18 to 24 hours (IV label).
- CrCl <15 mL/min (not on dialysis)
- Oral: CrCl 5–29, 250 to 500 mg every 18 hours (label). IV: CrCl 5–29, 200 to 400 mg every 18 to 24 hours (IV label). Below 5 not on dialysis: not addressed; specialist input.
- Hemodialysis (intermittent)
- Oral: 250 to 500 mg every 24 hours, after dialysis (label). IV: dialysis not addressed in the IV label; specialist input.
- Peritoneal dialysis
- Oral: 250 to 500 mg every 24 hours (the label groups hemodialysis and peritoneal dialysis). IV: dialysis not addressed in the IV label; specialist input. For PD-associated peritonitis (ISPD 2022): intraperitoneal continuous maintenance 50 mg/L (no intermittent IP data); systemic oral 500–750 mg daily (750 mg twice daily for CCPD) (ISPD Table 6).
- CRRT
- Not in label. Published CRRT regimens: 200–400 mg IV every 8–12 hours by effluent rate (Li 2020); specialist input.
- Dialyzable? Minimal: less than 10% removed by hemodialysis or peritoneal dialysis (label).
- Monitoring Tendon rupture, QT prolongation, dysglycemia, central nervous system effects; crystalluria (keep hydrated).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dosing.
- eGFR 30–59
- No information for CrCl <50 mL/min/1.73 m2 in children (excluded from trials) (label). Specialist input.
- eGFR 15–29
- No information (label). Specialist input.
- eGFR <15 (not on dialysis)
- No information (label). Specialist input.
- Hemodialysis (intermittent)
- No pediatric data.
- Peritoneal dialysis
- No pediatric data.
- CRRT
- No pediatric data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.3 Dosage Modifications in Patients with Renal Impairment Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment.
Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction. Dosage guidelines for use in patients with renal impairment are shown in Table 4. Table 4: Recommended Starting and Maintenance Doses for Adult Patients with Impaired Renal Function Creatinine Clearance (mL/min) Dose > 50 See Usual Dosage. 30–50 250–500 mg every 12 hours 5–29 250–500 mg every 18 hours Patients on hemodialysis or Peritoneal dialysis 250–500 mg every 24 hours (after dialysis) When only the serum creatinine concentration is known, the following formulas may be used to estimate creatinine clearance: Men - Creatinine clearance (mL/min) = Weight (kg) x (140–age) 72 x serum creatinine (mg/dL) Women - 0.85 x the value calculated for men.
The serum creatinine should represent a steady state of renal function. In patients with severe infections and severe renal impairment, a unit dose of 750 mg may be administered at the intervals noted above. Patients should be carefully monitored. Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of cUTI and pyelonephritis.
No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (that is, creatinine clearance of < 50 mL/min/1.73 m²).
8.6 Renal Impairment Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternative pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. Nonetheless, some modification of dosage is recommended, particularly for patients with severe renal dysfunction [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
Renal Impairment In patients with reduced renal function, the half-life of ciprofloxacin is slightly prolonged. Dosage adjustments may be required [see Use in Specific Populations (8.6) and Dosage and Administration (2.3)].
Dosing: Hepatic impairment
8.7 Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed. The pharmacokinetics of ciprofloxacin in patients with acute hepatic insufficiency, have not been studied.
US FDA labelDosing: Pediatric
- Approved ages
- Complicated urinary tract infection (cUTI) and pyelonephritis: 1 to 17 years. Inhalational anthrax and plague: birth to 17 years. Not a drug of first choice in children (label).
- Usual dose
- cUTI/pyelonephritis: 10 to 20 mg/kg every 12 hours. Anthrax: 15 mg/kg every 12 hours. Plague: 15 mg/kg every 8 to 12 hours (oral, label).
- Maximum dose
- cUTI: 750 mg per dose, even above 51 kg. Anthrax and plague: 500 mg per dose (label).
- Neonates
- Neonates: anthrax and plague indications start from birth at 15 mg/kg; no neonatal kidney guidance. Specialist input.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Although effective in clinical trials, CIPRO is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to controls. Quinolones, including CIPRO, cause arthropathy (arthralgia, arthritis), in juvenile animals [see Warnings and Precautions (5.13) and Nonclinical Toxicology (13.2)].
Complicated Urinary Tract Infection and Pyelonephritis CIPRO is indicated for the treatment of cUTI and pyelonephritis due to Escherichia coli in pediatric patients 1 to 17 years of age. Although effective in clinical trials, CIPRO is not a drug of first choice in the pediatric population due to an increased incidence of adverse reactions compared to the controls, including events related to joints and/or surrounding tissues [see Adverse Reactions (6.1) and Clinical Studies (14.1)].
Inhalational Anthrax (Post-Exposure) CIPRO is indicated in pediatric patients from birth to 17 years of age, for inhalational anthrax (post-exposure). The risk-benefit assessment indicates that administration of ciprofloxacin to pediatric patients is appropriate [see Dosage and Administration (2.2) and Clinical Studies (14.2)].
Plague CIPRO is indicated in pediatric patients from birth to 17 years of age, for treatment of plague, including pneumonic and septicemic plague due to Yersinia pestis (Y. pestis) and prophylaxis for plague. Efficacy studies of CIPRO could not be conducted in humans with pneumonic plague for feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals.
The risk-benefit assessment indicates that administration of CIPRO to pediatric patients is appropriate [see Indications and Usage (1.8), Dosage and Administration (2.2) and Clinical Studies (14.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as CIPRO. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported.
Caution should be used when prescribing CIPRO to elderly patients especially those on corticosteroids. Patients should be informed of this potential adverse reaction and advised to discontinue CIPRO and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur. [see Boxed Warning, Warnings and Precautions (5.2), and Adverse Reactions (6.2)].
Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see Warnings and Precautions (5.9)]. In a retrospective analysis of 23 multiple-dose controlled clinical trials of CIPRO encompassing over 3500 ciprofloxacin-treated patients, 25% of patients were greater than or equal to 65 years of age and 10% were greater than or equal to 75 years of age.
No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals on any drug therapy cannot be ruled out. Ciprofloxacin is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function.
No alteration of dosage is necessary for patients greater than 65 years of age with normal renal function. However, since some older individuals experience reduced renal function by virtue of their advanced age, care should be taken in dose selection for elderly patients, and renal function monitoring may be useful in these patients [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
In general, elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using CIPRO with concomitant drugs that can result in prolongation of the QT interval (for example, class IA or class III antiarrhythmics) or in patients with risk factors for torsade de pointes (for example, known QT prolongation, uncorrected hypokalemia) [see Warnings and Precautions (5.12)].
Administration
2.4 Important Administration Instructions With Multivalent Cations Administer CIPRO at least 2 hours before or 6 hours after magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate) or sucralfate; Videx ® (didanosine) chewable/buffered tablets or pediatric powder for oral solution; other highly buffered drugs; or other products containing calcium, iron or zinc. With Dairy Products Concomitant administration of CIPRO with dairy products (like milk or yogurt) or calcium-fortified juices alone should be avoided since decreased absorption is possible; however, CIPRO may be taken with a meal that contains these products. Hydration of Patients Receiving CIPRO Assure adequate hydration of patients receiving CIPRO to prevent the formation of highly concentrated urine. Crystalluria has been reported with quinolones. Instruct the patient of the appropriate CIPRO administration [see Patient Counseling Information (17)]. Missed Doses If a dose is missed, it should be taken anytime but not later than 6 hours prior to the next scheduled dose. If less than 6 hours remain before the next dose, the missed dose should not be taken and treatment should be continued as prescribed with the next scheduled dose. Double doses should not be taken to compensate for a missed dose. Splitting CIPRO Tablets CIPRO Tablets, 250 mg and 500 mg are functionally scored tablets which can be split into one-half at the scored line to provide a 125 mg and 250 mg strength, respectively.
2.5 Directions for Reconstitution of the CIPRO Microcapsules for Oral Suspension CIPRO Oral Suspension is supplied in 5% (5 g ciprofloxacin in 100 mL) and 10% (10 g ciprofloxacin in 100 mL) strengths. CIPRO oral suspension is composed of two components (microcapsules and diluent) that must be combined prior to dispensing. Table 5: Appropriate Dosing Volumes of the Reconstituted Oral Suspensions Dose 5% (250 mg/5 mL) 10% (500 mg/5 mL) 250 mg 5 mL 2.5 mL 500 mg 10 mL 5 mL 750 mg 15 mL 7.5 mL Preparation of the suspension: Step1 The small bottle contains the microcapsules, the large bottle contains the diluent. Step 2 Open both bottles. Child-proof cap: Press down according to instructions on the cap while turning to the left. Step 3 Pour the microcapsules completely into the larger bottle of diluent. Do not add water to the suspension. Step 4 Remove the top layer of the diluent bottle label (to reveal the CIPRO Oral Suspension label). Close the large bottle completely according to the directions on the cap and shake vigorously for about 15 seconds. The suspension is ready for use. Step 5: Write the expiration date of the re-constituted oral suspension on the bottle label. Reconstituted product may be stored below 30°C (86°F) for 14 days. Protect from freezing. No additions should be made to the mixed final ciprofloxacin suspension. CIPRO Oral Suspension should not be administered through feeding or NG (nasogastric) tubes due to its physical characteristics. Step 1 Step 2 Step 3 Step 4
2.6 Administration Instructions for CIPRO for Oral Suspension After Reconstitution • Shake CIPRO Oral Suspension vigorously each time before use for approximately 15 seconds. • Administer CIPRO Oral Suspension using the co-packaged graduated teaspoon provided for the patient (see Figure 1) Figure 1: Co-packaged 5 mL graduated teaspoon The Co-packaged graduated teaspoon (5mL) is provided, with markings for 1/2 (2.5 mL) and 1/1 (5 mL) • After use, clean the graduated teaspoon under running water with dish detergent and dry thoroughly. • Do Not chew the microcapsules in the CIPRO Oral Suspension, instead swallow them whole. • Water may be taken afterwards. • Reclose the bottle properly after each use according to instructions on the cap. • After treatment has been completed, CIPRO Oral Suspension should not be reused. gradated spoon
US FDA labelDosage forms
Philippines
- Film-coated tablet: 1 g, 250 mg, 500 mg, 750 mg
- ) solution for iv infusion: 2 mg/mL (200 mg/100 mL, 4 mg/mL (400 mg/100 mL, 200 mg/100 mL (2 mg/mL
- Solution for iv infusion: 2 mg/mL, 200 mg/100 mL, 400 mg/100 mL
- Tablet: 500 mg
- Solution for infusion: 2 mg/mL
- ) solution for i.v. infusion: 2 mg/mL (100 mg/50 mL, 2 mg/mL (200 mg/100 mL, 200 mg/100 mL (2 mg/mL
- ) iv infusion: 200 mg/100 mL (2 mg/mL
- Solution for injection: 2 mg/mL
- ) solution for injection: 2 mg/mL (200 mg/100 mL, 200 mg/100 mL (2 mg/mL
- Ophthalmic solution: 3 mg/mL
and 14 more forms; see the products table.
Registered products in the Philippines
201 products registered with the Food and Drug Administration (FDA) Philippines list Ciprofloxacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products201
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Aarciflox 500Ciprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu-Alu Blister x 10's (Box of 100's) | Rx | Pinnacle Life Science Private LimitedIndia | S.M.H.P. Marketing & Consultancy | DRP-17055 | Sep 19, 2030 | |
AciprexCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Drops)5 mL in 10 mL-capacity LDPE Plastic Dropper Tipped Bottle (Box of 1's) | Rx | ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines | Trader: SENSOMED PHILS., INC. | DR-XY42125 | Jun 17, 2028 | |
AciproCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-5459 | Sep 13, 2028 | |
AcucipCiprofloxacin | 2 mg/mL Solution For IV InfusionHDPE Bottle x 100 mL (Box of 1's) | Rx | Aculife Healthcare Private LimitedIndia | Blue Global (FZE) | DRP-14816 | Jan 15, 2029 | |
AeciproCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China | DYNASTY PHARMACEUTICALSImporter: AGLOBAL CARE, INC. | DRP-5459-01 | Sep 13, 2028 | |
AffoproCiprofloxacin (as Lactate) | 2 mg/mL Solution for Infusion (I.M./I.V.)100 mL Clear LDPE Bottle (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | Affomedz, Inc.Importer: I.E. Medica, Inc. | DRP-2141-02 | Apr 29, 2028 | |
AltofloxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-495-05 | Sep 21, 2027 | |
AmbiciproCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for I.V. InfusionLDPE Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3333 | Feb 18, 2038 | |
AmkofloxCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Biopharma Laboratories LimitedBangladesh | AMK Pharma International TradingImporter: JF Draf Pharmaceuticals Corporation | DRP-1976-02 | Oct 28, 2029 | |
Ancipro-500Ciprofloxacin (as hydrochloride) | 500 mg Film-coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | Rx | Hiral Labs LimitedIndia | Aglobal Care, Inc. | DRP-12271 | Jul 7, 2027 | |
Ancipro-500Ciprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's) | Rx | S Kant Healthcare LimitedIndia | AGlobal Care, Inc. | DRP-16826 | Jun 21, 2030 | |
AxacipCiprofloxacin (As Lactate) | 200 mg/100 mL (0.2 % w/v) Solution For IV InfusionLdpe Plastic Bottle X 100 Ml | Rx | — | — | DRP-8459 | Feb 7, 2030 | |
AzelonCiprofloxacin | 2 mg/mL Solution for Infusion (IV)LDPE Bottle x 100 mL (Box of 1's) | Rx | Aishwarya HealthcareIndia | Arvincare Pharma Inc. | DRP-3460 | Dec 28, 2029 | |
BaciproCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for Intravenous (I.V.) InjectionPlastic Bottle x 100 mL (Box of 1's) | Rx | Otsuka Pharmaceutical India Private LimitedIndia | Zuellig Pharma CorporationImporter: Otsuka (Philippines) Pharmaceutical, Inc. | DRP-1089 | Jan 5, 2027 | |
BactifloxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Uni MedicolabsIndia | Sigma Medical Solution Trading Co. Inc.Importer: Greencore Pharma Inc. | DRP-14933-01 | Feb 16, 2029 | |
BruciproCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Clear Orange PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-4710 | Sep 13, 2028 | |
CetraxalCiprofloxacin (as hydrochloride) | 2 mg/mL (0.2% w/v) Otic Solution (Ear Drops)0.5 mL-capacity LDPE ampoule packed with aluminum foil overwrap pouches x 0.25 mL-net content (Box of 15's) | Rx | Laboratorios Salvat, S.A.Spain | Hyphens Pharma Philippines, Inc.Trader: Hyphens Pharma Pte. Ltd. | DR-XY47355 | Aug 12, 2031 | |
CiclodinCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DR-XY44015 | Dec 18, 2029 | |
Ciclodin IVCiprofloxacin (as hydrochloride) | 2 mg/mL (100 mg/50 mL) Solution for I.V. InfusionUSP Type II Clear Glass vial x 100 mL (Box of 1's) | Rx | Siu Guan Chemical Industry Company, LimitedTaiwan | Justright Healthcare Inc.Importer: Caan Pharmaceutical Co., Inc. | DRP-3261-01 | Jan 23, 2032 | |
Ciclodin IVCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV Injection100 mL Non-PVC bag with polypropylene twist-off port enclosed in Aluminum overwrap pouch (Box of 30's) | Rx | HK inno.N CorporationKorea | JustRight Healthcare Inc.Trader: NeoGenex Inc. | DR-XY48140 | Jun 28, 2027 | |
Ciclodin IVCiprofloxacin | 2mg/mL (400mg/200mL) Solution for IV Injection200 mL Non-PVC bag with polypropylene twist-off in Aluminum overwrap pouch port (Box of 10's and 20's) | Rx | HK inno.N CorporationKorea | JustRight Healthcare Inc. | DR-XY48159 | Jul 1, 2027 | |
CIDROXALCIPROFLOXACIN (as lactate) | Solution for Infusion (IV) 2 mg/mLColorless Glass Vial with Orange Flip-off Seal x 100 mL and 200 mL (Box of 1's) | Rx | Pharmathen S.A.Greece | Jf Draf Pharmaceuticals CorporationImporter: JF DRAF PHARMACEUTICALS CORPORATION | DRP-835 | Dec 12, 2030 | |
CiflamaxCiprofloxacin (as hydrochloride) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's) | Rx | XL Laboratories Pvt. Ltd.India | Medchoice Urology Nephro Pharma Inc.Importer: Ambica International Corporation | DRP-3711-02 | Jul 24, 2027 | |
CiflomedCiprofloxacin (as hydrochloride) | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals, Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-276-06 | Sep 30, 2027 | |
CifrextabCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Ambica International Corporation | DRP-1261-07 | Feb 9, 2037 | |
Cifrextab 750Ciprofloxacin (as hydrochloride) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Rexmed Pharmaceutical SalesImporter: Ambica International Corporation | DRP-3711-03 | Jul 24, 2027 | |
CiloxanCiprofloxacin (as Hydrochloride) | 3 mg/mL (0.3% w/v) Sterile Ophthalmic SolutionLDPE natural droptainer x 5 mL | Rx | Alcon-Couvreur NVBelgium | Importer: Novartis Healthcare Philippines, Inc. | DR-XY16924 | Feb 6, 2027 | |
CipcorCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Ambicare Pharmaceuticals Inc.Trader: Unosource Pharma Ltd. | DRP-3568 | Feb 9, 2030 | |
Cipfast-500Ciprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s and 100’s) | Rx | XL Laboratories Pvt. Ltd.India | Speed Cure PharmaImporter: Ambica International Corporation | DRP-1261 | Nov 13, 2030 | |
Cipfast-750Ciprofloxacin (as hydrochloride) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 100's) | Rx | XL Laboratories Pvt. Ltd.India | Speed Cure PharmaImporter: Ambica International Corporation | DRP-3711 | Jul 24, 2027 | |
CipflowCiprofloxacin (as lactate) | 2 mg/mL Solution for Infusion (IV)Colorless Glass Vial with Orange Flip-off Seal x 200 mL (Box of 1's) | Rx | Pharmathen S.A.Greece | Bansan Pharma DistributorImporter: JF Draf Pharmaceuticals Corporation | DRP-835-02 | Dec 12, 2030 | |
CiplifeCiprofloxacin | 2 mg/mL Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-7921 | Aug 1, 2027 | |
Ciplon DS IVCiprofloxacin (as Lactate) | 400 mg/100 mL Solution for IV Infusion100 mL Clear Type I Glass Vial sealed with grey bromobutyl stopper and blue plastic flip-off cap in a box (Each bottle has a plastic hanger for use during administration) | Rx | Techno Drugs Ltd.Bangladesh | Bridgemark Marketing | DRP-3324 | Mar 24, 2029 | |
CiploxacCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Cassandras Care Pharmaceutical DistributorImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd | DRP-5976-05 | Feb 11, 2030 | |
CiploxacCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 20's and 100's) | Rx | Agio Pharmaceuticals Ltd.India | Cassandras Care Pharmaceutical DistributorImporter: Ambica International Corporation | DRP-6299-01 | Sep 30, 2030 | |
CiplumeCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3%w/v) Sterile Ophthalmic Solution (Drops)5 mL LDPE Bottle (Box of 1's) | Rx | Axa Parenterals LimitedIndia | Brady Pharma Inc. | DRP-12088 | Sep 15, 2031 | |
CipremCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Premier Pharmaceuticals Marketing Corp.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702-06 | Sep 16, 2028 | |
CipremCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletAlu / PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Premier Pharmaceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc. | DRP-16412-02 | Mar 10, 2030 | |
Cipro-VCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Otic Solution (Ear Drops)LDPE dropper-tipped plastic bottle in 5 mL (net content) Box of 1's | Rx | EL Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY33421 | Aug 2, 2027 | |
CiprobayCiprofloxacin (As Lactate) | 2 mg/mL Solution for Intravenous (IV) Infusion250 mL-capacity Type II colorless siliconized glass vial with gray chlorobutyl stopper and aluminum-shell polypropylene plastic button flanged closure (Box of 1 vial x 200 mL-net content) 100 mL-capacity Type II colorless siliconized glass vial with gray chlorobutyl stopper and aluminum-shell polypropylene plastic button flanged closure (Box of 1 vial x 100 mL-net content) | Rx | Fresenius Kabi Italia S.R.L.Italy | Bayer Philippines, Inc. | DR-XY48228 | Jul 26, 2027 | |
CiprobayCiprofloxacin (as lactate) | 2 mg/mL Solution for IV InfusionIn siliconized vial x 100 mL and 200 mL Box of 1's | Rx | Bayer AGGermany | Importer: Bayer Philippines, Inc. | DR-XY5324 | Jun 30, 2029 | |
CiprobayCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu-PVC/PVDC Blister Foil x 10's (Box of 50's) | Rx | Bayer Healthcare Manufacturing S.R.LItaly | Bayer Philippines, Inc. | DR-XY48775 | Jun 20, 2028 | |
CiprobayCiprofloxacin | 500 mg Film-Coated TabletAlu/PP Blister Pack x 10's (Box of 50's) | Rx | Bayer AGGermany | Importer: Bayer Philippines, Inc. | DRP-7194 | Sep 12, 2028 | |
CiproconCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Ophthalmic SolutionCollapsible plastic bottle x 10 mL with plastic cap and nozzle (Box of 1's) | Rx | Indiana OphthalmicsIndia | Medinova Pharmaceutical Inc | DRP-16377 | Feb 24, 2030 | |
Ciprodan-500Ciprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-1261-06 | Feb 9, 2037 | |
Ciprodan-750Ciprofloxacin (as hydrochloride) | 750 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-3711-01 | Jul 24, 2027 | |
CiprodenCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL polypropylene bottle with cap (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Cyden Medicale Trading Inc.Importer: PhilRx Pharma Inc. | DRP-12973-02 | Nov 11, 2027 | |
CiprodexCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletClear PVC / Alu Blister Pack x 10's (Box of 100's) | Rx | Endure Medical Inc.Philippines | Importer: Endure Medical Inc. | DR-XY40350 | Nov 28, 2028 | |
CiprodexCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu / Clear Orange PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Endure Medical, Inc.Importer: Ambica International Corporation | DRP-4710-04 | Sep 13, 2028 | |
Ciprodin-FCCiprofloxacin Hydrochloride | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-6045 | Oct 14, 2028 | |
CiprofedCiprofloxacin (as hydrochloride) | Film-Coated Tablet 500 mgAlu/Light Blue PVC Blister Pack x 10's (Box of 100's); Alu/Light Blue PVC Blister Pack x 14's (Box of 14's in DOH prescribed artwork) | Rx | Sapphire Lifesciences Pvt. LtdIndia | 777 Red Pharma IncImporter: Nelpa Lifesciences, Inc. | DRP-3801-01 | Nov 18, 2030 | |
CiprofloCiprofloxacin (as hydrochloride) | 2 mg/mL (100 mg/50 mL) Solution for I.V. InfusionClear USP Type II Glass Vial x 100 mL (Box of 1’s) | Rx | Siu Guan Chemical Ind. Co., Ltd.Taiwan | Caan Pharmaceutical Co.,Inc. | DRP-3261 | May 31, 2031 | |
CiprogenCiprofloxacin (as Lactate) | 2 mg/mL Solution for Infusion (IV)Type II Clear Glass Vial x 100 mL (Box of 1's) | Rx | Taiwan Biotech Co., Ltd.China | Pharma King DistributorImporter: Largen Med Inc. | DRP-988-01 | Feb 5, 2029 | |
CiprogylCiprofloxacin (As Hydrochloride) | 2 mg/mL (200 mg/100 mL) Solution for Intravenous InjectionLDPE bottle x 100 mL (Box of 1's) | Rx | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India | Medinova Pharmaceuticals Inc. | DRP-11455 | Mar 14, 2027 | |
CiprojazCiprofloxacin (as hydrochloride) | 500 mg TabletPVC/Blister Pack x 10's (Box of 100's) | Rx | CSPC Ouyi Pharmaceutical Co. LtdChina | Jazmark PharmaceuticalImporter: AMB HK Enterprises Inc. | DRP-8394-01 | Sep 25, 2029 | |
Ciprojaz 400Ciprofloxacin (as Lactate) | 400 mg/100 mL Solution for IV Infusion100 mL clear type I glass vial sealed with grey bromobutyl stopper and blue plastic flip-off cap in a box / (each bottle has a plastic hanger for use during administration) | Rx | Techno Drugs Ltd.Bangladesh | Jazmark PharmaceuticalImporter: Bridgemark Marketing | DRP-3324-03 | Mar 24, 2029 | |
CiproklearCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16412-01 | Mar 10, 2030 | |
CiprolaxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | Rx | Umedica Laboratories Pvt. Ltd.India | Medicamenta IncImporter: Suhitas Pharmaceuticals Inc. | DRP-1034 | Aug 27, 2028 | |
CiprollenCiprofloxacin (as Hydrochloride) | 2 mg/mL (200 mg/100 mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100 mL (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11221-01 | Feb 15, 2027 | |
CipromarCiprofloxacin | 500mg Film-Coated TabletBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Marilz Pharmaceutical CorporationTrader: Interhealthcare Pharmaceuticals Inc. | DRP-495-10 | Sep 21, 2027 | |
Cipromarck 400Ciprofloxacin (as Lactate) | 400 mg / 100 mL Solution for IV Infusion100 mL Clear Type I Glass Vial sealed with grey bromobutyl stopper and blue plastic flip-off cap in a box / (Each bottle has a plastic hanger for use during administration) | Rx | Techno Drugs Ltd.Bangladesh | Promarck Pharma and Medical Supplies TradingImporter: Bridgemark Marketing | DRP-3324-02 | Mar 24, 2029 | |
CiprometCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu-Clear Pvc Blister Pack X 10's (Box of 50's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: Metro Pharma Philippines, Inc. | DRP-1359 | May 30, 2031 | |
CipronatCiprofloxacin | 2 mg/mL Solution for InfusionClear Glass Bottle x 100 mL and 200 mL | Rx | Yuria - Pharm Ltd.Ukraine | Sannovex Pharmaceutical Distributor | DR-XY45466 | Jun 23, 2031 | |
CipronovaCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Medinova Pharmaceutical Inc. | DRP-16456 | Mar 18, 2030 | |
CiprophilCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletClear PVC/PVDC Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-3666 | Aug 10, 2027 | |
CiproprimeCiprofloxacin | 200 mg/100 mL (2 mg/mL) Solution for IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Primus Medicus Distributors Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702-04 | Sep 16, 2028 | |
CiproquinCiprofloxacin | 2 mg/mL Solution for Intravenous Infusion100 mL Non PVC Bag | Rx | Otsuka Pharmaceutical India Private LimitedIndia | Otsuka (Phils.) Pharmaceutical, Inc. | DR-XY42327 | Jul 31, 2028 | |
CiprosanCiprofloxacin (as hydrochloride) | Film-Coated Tablet 500 mgAlu/Light Blue PVC Blister Pack x 10's (Box of 100's); Alu/Light Blue PVC Blister Pack x 14's (Box of 14's in DOH prescribed artwork) | Rx | Sapphire Lifesciences Pvt. LtdIndia | Nelpa Lifesciences, Inc. | DRP-3801 | Nov 18, 2030 | |
Ciprosan-3Ciprofloxacin (as hydrochloride) | 2 mg/mL (200 mg/100 mL) Solution for Injection (IV Infusion)White LDPE Bottle Sealed with Cap x 100 mL (Box of l's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11221 | Feb 15, 2027 | |
CiprosaphCiprofloxacin (as hydrochloride) | 4 mg/mL (400 mg/ 100 mL) Solution for IV InfusionLDPE bottle x 100 mL (Box of 1's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-16569 | Jun 5, 2030 | |
CiprosaveCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 100's) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., LtdChina | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-5459-04 | Sep 13, 2028 | |
CiprosenzCiprofloxacin (as lactate) | 2 mg/mL Solution for Injection (IV)Clear Colorless USP Type I Glass Vial x 100 mL | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Pharmaessence Inc.Importer: H & B Pharma International Inc. | DRP-1750-04 | Jun 16, 2028 | |
CiprosonCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL Box of 1's | Rx | Amanta Healthcare Ltd.India | Sonchel Pharma DistributorsImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702-05 | Sep 16, 2028 | |
CiprotamCiprofloxacin Hydrochloride | 2 mg / mL (200 mg / 100 mL) Solution for Intravenous InjectionLDPE Bottle x 100 mL (Box of 1's) | Rx | — | Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc. | DRP-11455-01 | Mar 14, 2027 | |
CiprotamCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for Injection (IV Infusion)Clear Colorless LDPE Bottle x 100 mL in BOPP Film (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Tamiga Pharmaceuticals SupplyImporter: Medinova Pharmaceutical Inc. | DRP-17677-01 | Feb 16, 2031 | |
CiprotedCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Umedica Laboratories Pvt. Ltd.India | Littman Drug CorporationImporter: Suhitas Pharmaceuticals Inc. | DRP-1034-03 | Aug 27, 2028 | |
CiprotedCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Union Korea Pharm Co., Ltd.Korea | Littman Drug CorporationImporter: H & B Pharma International Inc. | DRP-7370 | Oct 14, 2030 | |
CiprovestCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 100's) | Rx | SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China | EURO-CARE PRODUCT PHILIPPINESImporter: AGLOBAL CARE, INC. | DRP-5459-03 | Sep 13, 2028 | |
CiprovueCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL polypropylene bottle with cap (Box of 1’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | CV Clearvue Pharma, Inc.Importer: PhilRx Pharma Inc. | DRP-12973-03 | Nov 11, 2027 | |
CiprowellCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Mascot Health Series Pvt. Ltd.India | Wellchem Pharmaceutical Products | DRP-17040 | Sep 12, 2030 | |
CiptidCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702 | Sep 16, 2028 | |
CipuloxCiprofloxacin (as lactate) | 2mg/mL (200mg/100mL) Solution for IV InfusionPolypropylene (PP) Plastic Bottle x 100 mL (Box of 1's) | Rx | Shijiazhuang No.4 Pharmaceutical C., Ltd.China | Sahar International Trading, Inc. | DRP-7653 | Jun 5, 2028 | |
CirokCiprofloxacin | 2 mg/mL Solution for IV InfusionClear Colorless Vial with Rubber Stopper and Gray Flip-off Seal x 100 mL (Box of 1's) | Rx | Korea United Pharm. Inc.Korea | One Pharma Marketing Inc. | DR-XY28759 | Jul 9, 2030 | |
CirokCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | One Pharma Marketing Inc.Importer: Medinova Pharmaceutical Inc. | DRP-11724-01 | Apr 25, 2027 | |
Cirpo IVCiprofloxacin (as Lactate) | 2 mg/mL Solution for Injection (I.V.)Clear Colorless USP Type I Glass Vial x 100 mL | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: H & B Pharma International Inc. | DRP-1750-03 | Jun 16, 2028 | |
Cobay-500Ciprofloxacin Hydrochloride | 500 mg TabletAluminum Strip Foil x 10's (Box of 100's) | Rx | Millimed Co., Ltd.Thailand | MG Prime Pharmaceutical Inc.Importer: ATLANTIC PHARMACEUTICALS, INC. | DRP-2588 | Mar 4, 2029 | |
CpacCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Ophthalmic SolutionWhite Opaque LDPE Plastic Vial Sealed with White Cap and Nozzle x 5 mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Bliss Pharma Distribution and Consultancy Corp. | DRP-14511 | Sep 15, 2028 | |
CyfroxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Reyoung Pharmaceutical Co., Ltd.The People's Republic of China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12369 | Jul 26, 2032 | |
CyfroxCiprofloxacin (as hydrochloride) | 500 mg TabletPVC/Blister Pack x 10’s (Box of 100’s) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8394 | Sep 25, 2029 | |
DyfloxinCiprofloxacin (as hydrochloride) | 1 g Film-Coated TabletAlu-Clear PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Nurturemed Pharma, Inc. | DR-XY38666 | Oct 19, 2031 | |
DynaciproCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Dynasty PharmaceuticalsImporter: Ambicare Pharmaceuticals Inc.Trader: Unosource Pharma Ltd. | DRP-3568-05 | Feb 9, 2030 | |
Encif-500Ciprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Primedrug Marketing CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976 | Feb 11, 2030 | |
FarmfloxinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Clear Orange PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4710-02 | Sep 13, 2028 | |
FLOCIPCiprofloxacin (As Hydrochloride) | 2mg/mL Solution for InjectionWhite Transparent LDPE Bottle x 100mL (Box of 1's) | Rx | Albert David LimitedUP India | Medethix, Inc. | DRP-7848 | May 4, 2031 | |
FloproxaCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Sterile Solution (Drops)5 mL opaque LDPE plastic bottle with nozzle and HDPE cap (Box of 1's) | Rx | Indiana OphthalmicsIndia | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-14973 | Mar 5, 2029 | |
FlosicronCiprofloxacin (as hydrochloride) | 500 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-276 | Sep 30, 2027 | |
FloxacinCiprofloxacin | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's individual box Box of 100's | Rx | Emil Pharmaceutical Industries Pvt. Ltd.India | Iberica Verheilen Pharmaceuticals Group Corp.Importer: Verheilen Iberica Health Care Company Inc.Trader: Farma Iberica S.L. | DRP-3583 | Jul 6, 2027 | |
FloxavexCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Sannovex Pharmaceutical DistributorImporter: Aglobal Care, Inc. | DRP-13199-02 | Dec 27, 2027 | |
FloxazinCiprofloxacin (as hydrochloride) | 500mg TabletBlister pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Jiaa PharmaImporter: Hexagon Pharmaceuticals | DRP-276-07 | Sep 30, 2027 | |
FloxilCiprofloxacin (as lactate) | 2 mg/mL Solution for Injection (IV Infusion)LDPE Plastic Vial x 100mL & 200mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Endure Medical, Inc. | DR-XY32741 | Feb 2, 2031 | |
FloxzuCiprofloxacin (as Hydrochloride ) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DRP-393 | Mar 31, 2027 | |
FluxeranCiprofloxacin (as hydrochloride) | 500 mg TabletBlister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Eadriex Pharmaceuticals Phils., Inc.Trader: Gamot Philippines, Inc. | DR-XY29002 | Oct 2, 2031 | |
Go-FloxCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 100's) | Rx | SHIJIAZHUANG NO. 4 PHARMACEUTICAL CO., LTD.China | APPLIED PHARMACEUTICAL DISTRIBUTION INCImporter: AGLOBAL CARE, INC. | DRP-5459-02 | Sep 13, 2028 | |
Goflox-VCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Unosource Pharma Ltd. | DRP-3568-01 | Feb 9, 2030 | |
Goflox-VCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702-03 | Sep 16, 2028 | |
GoproxacinCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL polypropylene bottle with cap (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: PhilRx Pharma Inc. | DRP-12973-04 | Nov 11, 2027 | |
IprinCiprofloxacin | 200 mg/100 mL (2 mg/mL) Solution for Intravenous InfusionPolypropylene Bottle x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co. LtdChina | HNE Pharmaceutical DistributorImporter: Apothecon Drug Int’l Corp.Trader: Shanghai Pharmaceutical Co., Ltd | DR-XY42237 | Aug 14, 2028 | |
IprobacCiprofloxacin (as hydrochloride) | 500mg TabletBlister pack x 5's (Box of 20's) | Rx | The ACME Laboratories LimitedBangladesh | Remed Pharmaceuticals Inc.Importer: EURO GENERICS INTERNATIONAL PHILIPPINES INC. | DRP-1529-01 | May 17, 2027 | |
IprocinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Pvc Blister X 10's (Box of 30s and 50's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | — | DRP-6912 | Jul 7, 2031 | |
JingroCiprofloxacin | 2 mg/mL (200 mg/ 100 mL) Solution for IV InfusionLDPE bottle x 100 mL (Box of 1's) | Rx | Eurolife Healthcare Pvt. Ltd.India | Aglobal Care, Inc. | DRP-16556 | Sep 28, 2030 | |
Kercip 400Ciprofloxacin (as Lactate) | 400 mg/100 mL Solution for IV Infusion100 mL Clear Type I Glass Vial sealed with grey bromobutyl stopper and blue plastic flip-off cap in a box / Each bottle has a plastic hanger for use during administration | Rx | Techno Drugs Ltd.Bangladesh | Health Care Pharma and Medical Supplies DistributionImporter: Bridgemark Marketing | DRP-3324-01 | Mar 24, 2029 | |
KinogenCiprofloxacin (as Lactate) | 2 mg/mL Solution for Infusion (IV)Type II Clear Glass Vial x 100 mL (Box of 1's) | Rx | Taiwan Biotech Co., Ltd.China | Largen Med Inc. | DRP-988 | Feb 5, 2029 | |
Kipro-500Ciprofloxacin (As Hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10 blister packs x s (Box of 10 blister packs x 10 tablets) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13199 | Dec 27, 2027 | |
LaitunCiprofloxacin ( as Hydrochloride ) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Biopharma Laboratories LimitedBangladesh | Genace Pharma DistributorImporter: JF Draf Pharmaceuticals Corp. | DRP-1976-05 | Oct 28, 2029 | |
LewifloxCiprofloxacin Hydrochloride | 500mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | Lewison Pharmaceutical Corporation | DRP-6045-03 | Oct 14, 2028 | |
MedicipCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution CorporationTrader: Interhealthcare Pharmaceuticals, Inc. | DRP-495-03 | Sep 21, 2027 | |
MegafloxCiprofloxacin (as Lactate) | 2 mg/mL (200 mg/100 mL) Solution for I.V. Infusion | Rx | GEOFMAN PHARMACEUTICALS | SAHAR INTERNATIONAL TRADING INC. | DR-XY40351 | Nov 28, 2026 | |
MucolifarCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Vidar Pharmaceutical EnterprisesImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976-02 | Feb 11, 2030 | |
NircipCiprofloxacin | 2mg/mL (200mg/100mL) Solution for Intravenous InfusionLDPE bottle x 100mL (Box of 1's) | Rx | Aculife Healthcare Private LimitedIndia | Brady Pharma Inc. | DR-XY38543 | Oct 4, 2031 | |
NolcifCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Helande Kidney Care Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976-04 | Feb 11, 2030 | |
NoneCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for IV InfusionLDPE Plastic Bottle x 100 mL (Box of 1’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.Trader: Unosource Pharma Ltd. | DRP-3568-04 | Feb 9, 2030 | |
NoneCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV InfusionPolypropylene Bottle x 100 mL (Box of 1's) | Rx | Shijiazhuang No. 4 Pharmaceutical Co., Ltd.China | Connectwell Pharma Inc.Importer: Aglobal Care, Inc | DRP-5459-05 | Sep 13, 2028 | |
NoneCiprofloxacin (as Hydrochloride) | 250 mg Film-Coated TabletClear PVC/PVDC/ Aluminum Blister Pack x 10's ( Box of 100's) | Rx | Interphil Laboratories Inc.Philippines | Neodrug, Inc | DRP-3665-01 | Aug 10, 2027 | |
NoneCIPROFLOXACIN | 3 mg/mL(0.3% w/v) Sterile Ophthalmic Solution (Eye Drops)White LDPE with Plastic Bottle with Plug and Cap x 5mL (Box of 1's) | Rx | e.L Laboratories, Inc.Philippines | Trader: CELSUS PHARMACEUTICALS PHILS., INC. | DR-XY35704 | Apr 21, 2029 | |
NoneCiprofloxacin (hydrochloride) | 500 mg Film - Coated TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Marti-Lian Pharma Link | DRP-6912-04 | Jul 6, 2031 | |
NoneCiprofloxacin(as hydrochloride) | 500 mg Film Coated TabletClear PVC/PVDC/Aluminum Blister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories Inc.Philippines | Rose Pharmacy Incorporated | DRP-3666-01 | Aug 10, 2027 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletClear PVC/PVDC Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Interphil Laboratories Inc.Philippines | Neodrug, Inc. | DRP-3666-02 | Aug 10, 2027 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletClear PVC/PVDC Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Interphil Laboratories Inc.Philippines | St. Joseph Drugstore | DRP-3666-05 | Aug 10, 2027 | |
NoneCiprofloxacin (as hydrochloride monohydrate) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Unique Pharmaceutical Laboratories (A division of J.B. Chemicals and Pharmaceuticals Ltd.)India | Ritemed Phils., Inc. | DR-XY33466 | Jun 7, 2031 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Uni MedicolabsIndia | Qualifirst Health Inc.Importer: Greencore Pharma Inc. | DRP-14933-02 | Feb 16, 2029 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletClear PVC/PVDC Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-3666-06 | Aug 10, 2027 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Clear Orange PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-4710-01 | Sep 13, 2028 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Clear Orange PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4710-03 | Sep 13, 2028 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Interhealthcare Pharmaceuticals Inc. | DRP-495 | Sep 21, 2027 | |
NoneCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-5439 | Sep 15, 2029 | |
NoneCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976-01 | Feb 11, 2030 | |
NoneCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5976-06 | Feb 11, 2030 | |
NoneCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976-09 | Feb 11, 2030 | |
NoneCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 20's and Box of 100's) | Rx | Agio Pharmaceuticals Ltd.India | Providencia Medica Inc.Importer: Ambica International Corporation | DRP-6299 | Sep 30, 2030 | |
NoneCiprofloxacin Hydrochloride | 500 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-6045-01 | Oct 14, 2028 | |
NovacipCiprofloxacin | 2mg/mL (200mg/100mL) Solution for Injection (IV Infusion) | Rx | Eurolife Healthcare Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-17677 | Feb 16, 2031 | |
NovaflocinCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc. | DRP-16412 | Mar 10, 2030 | |
NovafloxCiprofloxacin (as Hydrochloride) | 3 mg/mL Sterile Ophthalmic SolutionLDPE White Plastic Bottle x 5 mL (Box of 1’s) | Rx | Laboratorios Ashford Lda.China | Marrion Pharma Inc. | DR-XY33952 | Nov 9, 2034 | |
PillxacinCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for I.V. InfusionLDPE Bottle x 100 mL Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III – Injectables)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3333-02 | Jul 30, 2037 | |
ProfiloxCiprofloxacin (as hydrochloride) | 500 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Filadams Pharma, Inc.Importer: Hexagon Pharmaceuticals | DRP-276-02 | Sep 30, 2027 | |
ProlaxaCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL polypropylene bottle with cap (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-12973 | Nov 11, 2027 | |
ProvexCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Endure Medical Inc.Importer: Endure Medical Inc | DR-XY44172 | Feb 16, 2030 | |
ProvifloxCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Providencia Medica Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-5976-07 | Feb 11, 2030 | |
ProxacinCiprofloxacin (as Hydrochloride) | 500 mg TabletBlister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | Phil. Pharmawelath, Inc. | DRP-1109-03 | Oct 17, 2031 | |
ProxilevCiprofloxacin | 2 mg/mL (0.2% w/v) Solution for I.V. InfusionLDPE Plastic Bottle x 100 mL Box of 1’s | Rx | Akums Drugs & Pharmaceuticals Ltd.India | HLM Pharmaceutical Inc.Importer: Ambicare Pharmaceuticals Inc.Trader: Unosource Pharma Ltd. | DRP-3568-06 | Feb 9, 2030 | |
ProxinCiprofloxacin (as lactate) | 2 mg/mL Solution for Injection (I.V.)Clear Colorless USP Type I Glass Vial x 100 mL | Rx | Union Korea Pharm Co., LtdRepublic of Korea | Primus Medicus Distributors Inc.Importer: H & B Pharma International Inc. | DRP-1750 | Jun 16, 2028 | |
ProxxenCiprofloxacin (as Hydrochloride) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10’s (Box of 50’s) | Rx | Biopharma Laboratories LimitedBangladesh | All-Bio Pharma, Inc.Importer: JF Draf Pharmaceuticals Corp. | DRP-1976-01 | Oct 28, 2029 | |
ProzinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Basic Pharmaceutical Corporation | DRP-2150-02 | Aug 17, 2029 | |
ProzinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Interhealthcare Pharmaceuticals Inc. | DRP-495-09 | Sep 21, 2027 | |
QuinocipCiprofloxacin (as lactate) | 2 mg/mL Solution for Infusion (I.M./I.V.)100 mL Clear LDPE Bottle (Box of 1's) | Rx | Ahlcon Parenterals (India) Ltd.India | I.E. Medica, Inc. | DRP-2141 | Apr 29, 2028 | |
QuinorylCiprofloxacin (as hydrochloride) | 500 mg Film-coated TabletBlister Pack x 5's (Box of 20's) | Rx | The ACME Laboratories LimitedBangladesh | United Pharma Plus (Unipharma) Inc.Importer: Euro Generics International Philippines Inc. | DRP-1529 | May 17, 2027 | |
RAYQUINCIPCiprofloxacin Hydrochloride | 0.3% (3mg/mL) Ophthalmic Solution (Drops)10 mL White HDPE Bottle Box of 1's | Rx | Indiana OphthalmicsIndia | RCL Ophthalmic SurgicalsImporter: Diafarm Inc.Trader: Stallion Laboratories Pvt. Ltd. | DRP-6047 | Mar 11, 2030 | |
RedfloxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | Umedica Laboratories Pvt. Ltd.India | Redrocks Pharma and Medical Supplies DistributionImporter: Suhitas Pharmaceuticals Inc. | DRP-1034-04 | Aug 27, 2028 | |
RofcipCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL (ox of 1's) | Rx | Amanta Healthcare Ltd.India | 228 Pharma TradingImporter: Ambica International CorporationTrader: Stallion Labortaories Pvt. Ltd. | DRP-4702-02 | Sep 16, 2028 | |
RoflexinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 tablets) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Aglobal Care, Inc. | DRP-13199-1 | Dec 27, 2027 | |
RoflexynCiprofloxacin | 500 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 100's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-11724-02 | Apr 22, 2027 | |
SeaprofloxCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletBlister Pack x 5's (Box of 20's) | Rx | The ACME Laboratories LimitedBangladesh | SEA-King Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-1529-02 | May 17, 2027 | |
SipraCiprofloxacin (as Hydrochloride) | 500mg Film-Coated TabletBlister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-1109 | Nov 13, 2030 | |
SITI-luxeCiprofloxacin (as Lactate) | 2 mg/mL Solution for Injection (I.V.)USP Type I Clear Glass Vial with Grey Rubber Stopper and Aluminum Seal fitted with Green Plastic Flip-off Cap + white Plastic Hanger x 100 mL (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt.) Ltd.Karachi Pakistan | Sahar International Trading Inc. | DRP-13547 | Sep 29, 2036 | |
SitifloxCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 30's and 100's | Rx | ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD.China | SAHAR INTERNATIONAL TRADING INC. | DR-XY45943 | Jun 29, 2027 | |
SutidCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's Box of 50's | Rx | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-495-02 | Sep 21, 2027 | |
SynproxinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-2150 | Aug 17, 2029 | |
TG-ZipCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/Pvc Blister Pack X 10's (Box of 30's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | TGIF Pharmaceutical Trading Inc. | DRP-6912-02 | Aug 6, 2031 | |
UnbrandedCiprofloxacin (as Hydrochloride) | 1 g Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY38679 | Oct 21, 2030 | |
UnbrandedCiprofloxacin (as Hydrochloride) | 2 mg/mL Solution for IV InfusionWhite transparent LDPE Bottle x 100 mL (Box of 1's) | Rx | Albert David LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc. | DRP-7848-01 | May 4, 2031 | |
UnbrandedCiprofloxacin | 3mg/mL (0.3% w/v) Sterile Otic Solution (Ear Drops)7.5mL White LDPE Plastic Bottle Plug and Cap (Box of 1's) | Rx | EL LABORATORIES, INC.Philippines | Trader: CELSUS PHARMACEUTICALS PHILS., INC. | DR-XY37008 | Nov 17, 2029 | |
Uni-CiproCiprofloxacin | 200 mg/100 mL (2 mg/mL) IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Amanta Healthcare Ltd.India | Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4702-01 | Sep 16, 2028 | |
UnifloxCiprofloxacin | 200 mg/100 mL Solution for I.V. InfusionPolypropylene infusion bottle (w/pull open cover) x 100 mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co. Ltd.China | Medbridge Inc.Importer: Apothecon Drug Int’l Corp..Trader: Shanghai Pharmaceutical Co., Ltd. | DRP-3044 | Aug 14, 2028 | |
UticinCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Pharmacare Products CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-5976-03 | Feb 11, 2030 | |
VistafloxCiprofloxacin (as hydrochloride) | 3 mg/mL (0.3% w/v) Ophthalmic Solution (Eye Drops)5 mL net content in 10 mL HDPE dropper-tipped plastic bottle (Box of 1's) | Rx | EL Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY33418 | Jul 20, 2027 | |
VonecipCiprofloxacin (As Lactate) | 2mg/mL (200 mg/100 mL) Solution For Infusion (IV)Type II colorless glass vial with 32 mm grey bromobutyl stopper and green flip-off cap x 100 mL (Box of 1's) | Rx | Aroma İlaç San. Ltd. ŞtiTurkey | Medinova Pharmaceutical, Inc.Trader: Polifarma İlaç San. Ve Tic. A.S. | DRP-12211 | Jun 30, 2027 | |
XafloquinCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Uni Medicolabs.India | Greencore Pharma, Inc. | DRP-14933 | Feb 16, 2029 | |
XalvosCiprofloxacin (as lactate) | 2 mg/mL solution for IV infusionColorless and transparent polypropylene bag with gray color rubber stopper and blue color plastic flip-top cover in PET pouch x 1's Box of 40's x 100 mL; Box of 20's x 200 mL | Rx | Daihan Pharm. Co., Ltd.Republic of Korea | Pharmasia-Cuvest Incorporated | DR-XY46893 | Feb 15, 2031 | |
XenofloxCiprofloxacin (as Hydrochloride) | 500 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Micro Labs LimitedIndia | ADP Pharma CorporationImporter: Brown & Burk Phils., Inc. | DRP-393-01 | Mar 31, 2027 | |
XiproCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletRed PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DRP-794 | Aug 20, 2030 | |
XiproconCiprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10 blister packs x 10 tablets) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Connectwell Pharma, Inc.Importer: AGlobal Care, Inc. | DRP-13199-03 | Dec 27, 2027 | |
XiprolifeCiprofloxacin | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL LDPE Plastic Bottle (Box of 1's) | Rx | Aishwarya LifesciencesIndia | Pharmakon Biotec Inc. | DRP-13414 | Feb 27, 2028 | |
XiproxCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for IV Infusion100 mL polypropylene bottle with cap (Box of 1's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Southmed Pharma CorporationImporter: PhilRx Pharma Inc. | DRP-12973-01 | Nov 11, 2027 | |
XYPENCiprofloxacin | 200 mg/100 mL (2 mg/mL) Solution for I.V. InfusionPolypropylene Bottle x 100mL (Box of 1’s) | Rx | Shijiazhuang No. 4 Pharmaceutical Co. LtdChina | Medhaus Pharma IncImporter: Apothecon Drug Int’l Corp. | DR-XY42238 | Aug 14, 2028 | |
XypenCiprofloxacin Hydrochloride | 500 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY36235 | Jul 13, 2029 | |
YokocipCiprofloxacin | 2 mg/mL (200 mg/100 mL)USP Type I Clear Glass Vial in 100 mL (Box of 1's) | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DR-XY38524 | Sep 22, 2030 | |
ZalvosCiprofloxacin (as lactate) | 2 mg/mL Solution for IV Infusion100 mL Polypropylene Bottle (Box of 10's); 200 mL Polypropylene Bottle (Box of 5's) | Rx | Demo SA Pharmaceutical IndustryGreece | PharmAsia-Cuvest, Incorporated | DR-XY28418 | Mar 17, 2028 | |
ZifloxCiprofloxacin ( as Hydrochloride ) | 500 mg Film coated TabletAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Biopharma Laboratories LimitedBangladesh | JF Draf Pharmaceuticals Corp. | DRP-1976 | Oct 28, 2029 | |
ZifloxCiprofloxacin (as Hydrochloride) | 750 mg Film-coated TabletAlu/Alu Blister Pack x 4's Box of 24's | Rx | Biopharma Laboratories LimitedBangladesh | JF Draf Pharmaceuticals Corporation | DRP-2332 | May 21, 2030 | |
Ziprimox ODCiprofloxacin (as hydrochloride) | 1 g Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY38010 | May 26, 2030 | |
ZIPRINCiprofloxacin (As Hydrochloride) | 500 mg Film-Coated TabletAlu / Pvc Blister Pack X 10's (Box of 30's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Chmi Pharma, Inc. | DRP-6912-01 | Jul 14, 2031 | |
ZiprinexCiprofloxacin (as Hydrochloride) | 500mg Film-coated TabletBlister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | CHMI Pharma, Inc. | DRP-1109-04 | Nov 13, 2030 | |
ZiprocapCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletClear PVC/PVDC Aluminum Foil Blister Strip x 10's (Box of 100's) | Rx | Interphil Laboratories Inc.Philippines | Nutramedica , Inc. | DRP-3666-03 | Aug 10, 2027 | |
ZiprominCiprofloxacin (as lactate) | 2 mg/mL (200 mg/100 mL) Solution for Intravenous InfusionPolypropylene Infusion Bottle x 100 mL with PP cap (Box of 1's) | Rx | Shijiazhuang No. 4 Pharmaceutical Co.,China | Global Pharmatrade | DR-XY49550 | Oct 14, 2030 | |
ZiprominCiprofloxacin (as lactate) | 200 mg/100 mL (2 mg/mL) Solution for I.V. Infusion100 mL Type I Glass Vial (Box of 1’s) | Rx | Jinling Pharmaceutical Co., Ltd. Zhejiang Tianfeng Pharmaceutical FactoryChina | Global Pharmatrade | DR-XY45504 | Jul 13, 2031 | |
ZiproxCiprofloxacin | 200 mg/100 mL (2 mg/mL) Solution for Injection (IV)USP Type I Clear Glass Vial x 100 mL Box of 1's | Rx | Myungmoon Pharmaceutical Co., LTD.Republic of Korea | Zyre Pharmaceuticals Corporation | DR-XY41119 | Aug 1, 2027 | |
ZiproxCiprofloxacin (as hydrochloride) | 500 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7100 | Apr 3, 2028 | |
ZiproxinCiprofloxacin (as Lactate) | 2 mg/mL Solution for Infusion (IV)Type II Clear Glass Vial x 100 mL (Box of 1's) | Rx | Taiwan Biotech Co., Ltd.China | Mark Ericson EnterprisesImporter: Largen Med Inc. | DRP-988-02 | Feb 5, 2029 | |
ZiproxylCiprofloxacin (as hydrochloride) | 500 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Neo Care Philippines, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-16412-03 | Mar 10, 2030 | |
(no brand name)Ciprofloxacin (as Hydrochloride) | 2 mg/mL Solution for IV InfusionLDPE Bottle x 100 mL (Box of 1's) | Rx | Unique Pharmaceuticals Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India | Ritemed Phils., Inc. | DR-XY29956 | Feb 19, 2031 | |
(no brand name)Ciprofloxacin (as hydrochloride) | 500 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Ratnamani Healthcare Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-11726 | Apr 22, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS
- Tablets: 250 mg, functionally scored and 500 mg, functionally scored (3)
- Oral Suspension: 5% (250 mg/5 mL), 10% (500 mg/5 mL) (3) 3.1 Tablets
- 250 mg, slightly yellowish, film-coated, round, functionally scored, imprinted with “BAYER” on one side and “CIP 250” on the other
- 500 mg, slightly yellowish, film-coated, capsule shaped, functionally scored, imprinted with “BAYER” on one side and “CIP 500” on the other 3.2 Oral Suspension
- 5% Oral Suspension: 250 mg ciprofloxacin per 5 mL after reconstitution
- 10% Oral Suspension: 500 mg ciprofloxacin per 5 mL after reconstitution
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Hypersensitivity and other serious reactions: Serious and sometimes fatal reactions (for example, anaphylactic reactions) may occur after the first or subsequent doses of CIPRO. Discontinue CIPRO at the first sign of skin rash, jaundice or any sign of hypersensitivity. (4.1, 5.6, 5.7)
- • Hepatotoxicity: Discontinue immediately if signs and symptoms of hepatitis occur. (5.8)
- • Clostridioides difficile -associated diarrhea: Evaluate if colitis occurs. (5.11)
- • QT Prolongation: Prolongation of the QT interval and isolated cases of torsade de pointes have been reported. Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (5.12, 7, 8.5)
5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and…
5.1 Disabling and Potentially Irreversible Serious Adverse Reactions Including Tendinitis and Tendon Rupture, Peripheral Neuropathy, and Central Nervous System Effects Fluoroquinolones, including CIPRO, have been associated with disabling and potentially irreversible serious adverse reactions from different body systems that can occur together in the same patient. Commonly seen adverse reactions include tendinitis, tendon rupture, arthralgia, myalgia, peripheral neuropathy, and central nervous system effects (hallucinations, anxiety, depression, insomnia, severe headaches, and confusion).
These reactions can occur within hours to weeks after starting CIPRO. Patients of any age or without pre-existing risk factors have experienced these adverse reactions [see Warnings and Precautions (5.2, 5.3, 5.4)]. Discontinue CIPRO immediately at the first signs or symptoms of any serious adverse reaction. In addition, avoid the use of fluoroquinolones, including CIPRO, in patients who have experienced any of these serious adverse reactions associated with fluoroquinolones.
5.2 Tendinitis and Tendon Rupture
5.2 Tendinitis and Tendon Rupture Fluoroquinolones, including CIPRO, have been associated with an increased risk of tendinitis and tendon rupture in all ages [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)]. This adverse reaction most frequently involves the Achilles tendon, and has also been reported with the rotator cuff (the shoulder), the hand, the biceps, the thumb, and other tendons.
Tendinitis or tendon rupture can occur, within hours or days of starting CIPRO, or as long as several months after completion of fluoroquinolone therapy. Tendinitis and tendon rupture can occur bilaterally. The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants.
Other factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis. Tendinitis and tendon rupture have also occurred in patients taking fluoroquinolones who do not have the above risk factors. Discontinue CIPRO immediately if the patient experiences pain, swelling, inflammation or rupture of a tendon.
Avoid fluoroquinolones, including CIPRO, in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture [see Adverse Reactions (6.2)].
5.3 Peripheral Neuropathy
5.3 Peripheral Neuropathy Fluoroquinolones, including CIPRO, have been associated with an increased risk of peripheral neuropathy. Cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving fluoroquinolones, including CIPRO.
Symptoms may occur soon after initiation of CIPRO and may be irreversible in some patients [see Warnings and Precautions (5.1) and Adverse Reactions (6.1, 6.2)]. Discontinue CIPRO immediately if the patient experiences symptoms of peripheral neuropathy including pain, burning, tingling, numbness, and/or weakness, or other alterations in sensations including light touch, pain, temperature, position sense and vibratory sensation, and/or motor strength in order to minimize the development of an irreversible condition.
Avoid fluoroquinolones, including CIPRO, in patients who have previously experienced peripheral neuropathy [see Adverse Reactions (6.1, 6.2)].
5.4 Central Nervous System Effects Psychiatric Adverse Reactions
5.4 Central Nervous System Effects Psychiatric Adverse Reactions Fluoroquinolones, including CIPRO, have been associated with an increased risk of psychiatric adverse reactions, including: toxic psychosis, psychotic reactions progressing to suicidal ideations/thoughts, hallucinations, or paranoia; depression, or self-injurious behavior such as attempted or completed suicide; anxiety, agitation, or nervousness; confusion, delirium, disorientation, or disturbances in attention; insomnia or nightmares; memory impairment. These reactions may occur following the first dose.
Advise patients receiving CIPRO to inform their healthcare provider immediately if these reactions occur, discontinue the drug, and institute appropriate care. Central Nervous System Adverse Reactions Fluoroquinolones, including CIPRO, have been associated with an increased risk of seizures (convulsions), increased intracranial pressure (pscudotumor cerebri), dizziness, and tremors.
CIPRO, like other fluoroquinolones, is known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. As with all fluoroquinolones, use CIPRO with caution in epileptic patients and patients with known or suspected CNS disorders that may predispose to seizures or lower the seizure threshold (for example, severe cerebral arteriosclerosis, previous history of convulsion, reduced cerebral blood flow, altered brain structure, or stroke), or in the presence of other risk factors that may predispose to seizures or lower the seizure threshold (for example, certain drug therapy, renal dysfunction).
If seizures occur, discontinue CIPRO and institute appropriate care [see Adverse Reactions (6.1) and Drug Interactions (7)].
5.5 Exacerbation of Myasthenia Gravis
5.5 Exacerbation of Myasthenia Gravis Fluoroquinolones, including CIPRO, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and requirement for ventilatory support, have been associated with fluoroquinolone use in patients with myasthenia gravis.
Avoid CIPRO in patients with known history of myasthenia gravis [see Adverse Reactions (6.2)].
5.6 Other Serious and Sometimes Fatal Adverse Reactions
5.6 Other Serious and Sometimes Fatal Adverse Reactions Other serious and sometimes fatal adverse reactions, some due to hypersensitivity, and some due to uncertain etiology, have been reported in patients receiving therapy with quinolones, including CIPRO. These events may be severe and generally occur following the administration of multiple doses.
Clinical manifestations may include one or more of the following:
- Fever, rash, or severe dermatologic reactions (for example, toxic epidermal necrolysis, Stevens-Johnson syndrome);
- Vasculitis; arthralgia; myalgia; serum sickness;
- Allergic pneumonitis;
- Interstitial nephritis; acute renal insufficiency or failure;
- Hepatitis; jaundice; acute hepatic necrosis or failure;
- Anemia, including hemolytic and aplastic; thrombocytopenia, including thrombotic thrombocytopenic purpura; leukopenia; agranulocytosis; pancytopenia; and/or other hematologic abnormalities. Discontinue CIPRO immediately at the first appearance of a skin rash, jaundice, or any other sign of hypersensitivity and supportive measures instituted [see Adverse Reactions (6.1, 6.2)].
5.7 Hypersensitivity Reactions
5.7 Hypersensitivity Reactions Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving fluoroquinolone therapy, including CIPRO. Some reactions were accompanied by cardiovascular collapse, acute myocardial ischemia with or without myocardial infarction, loss of consciousness, tingling, pharyngeal or facial edema, dyspnea, urticaria, and itching.
Only a few patients had a history of hypersensitivity reactions. Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, including intubation, as indicated [see Adverse Reactions (6.1, 6.2)].
5.8 Hepatotoxicity
5.8 Hepatotoxicity Cases of severe hepatotoxicity, including hepatic necrosis, life-threatening hepatic failure, and fatal events, have been reported with CIPRO. Acute liver injury is rapid in onset (range 1–39 days), and is often associated with hypersensitivity. The pattern of injury can be hepatocellular, cholestatic, or mixed.
Most patients with fatal outcomes were older than 55 years old. In the event of any signs and symptoms of hepatitis (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), discontinue treatment immediately. There can be a temporary increase in transaminases, alkaline phosphatase, or cholestatic jaundice, especially in patients with previous liver damage, who are treated with CIPRO [see Adverse Reactions (6.2, 6.3)].
5.9 Risk of Aortic Aneurysm and Dissection
5.9 Risk of Aortic Aneurysm and Dissection Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients. The cause for the increased risk has not been identified. In patients with a known aortic aneurysm or patients who are at greater risk for aortic aneurysms, reserve CIPRO for use only when there are no alternative antibacterial treatments available.
5.10 Serious Adverse Reactions with Concomitant Theophylline
5.10 Serious Adverse Reactions with Concomitant Theophylline Serious and fatal reactions have been reported in patients receiving concurrent administration of CIPRO and theophylline. These reactions have included cardiac arrest, seizure, status epilepticus, and respiratory failure. Instances of nausea, vomiting, tremor, irritability, or palpitation have also occurred.
Although similar serious adverse reactions have been reported in patients receiving theophylline alone, the possibility that these reactions may be potentiated by CIPRO cannot be eliminated. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate [see Drug Interactions (7)].
5.11 Clostridioides difficile
5.11 Clostridioides difficile -Associated Diarrhea Clostridioides difficile (C. difficile)- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CIPRO, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing isolates of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and institute surgical evaluation as clinically indicated [see Adverse Reactions (6.1)].
5.12 Prolongation of the QT Interval
5.12 Prolongation of the QT Interval Some fluoroquinolones, including CIPRO, have been associated with prolongation of the QT interval on the electrocardiogram and cases of arrhythmia. Cases of torsade de pointes have been reported during postmarketing surveillance in patients receiving fluoroquinolones, including CIPRO.
Avoid CIPRO in patients with known prolongation of the QT interval, risk factors for QT prolongation or torsade de pointes (for example, congenital long QT syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. Elderly patients may also be more susceptible to drug-associated effects on the QT interval [see Adverse Reactions (6.2), Use in Specific Populations (8.5)].
5.13 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals
5.13 Musculoskeletal Disorders in Pediatric Patients and Arthropathic Effects in Animals CIPRO is indicated in pediatric patients (less than 18 years of age) only for cUTI, prevention of inhalational anthrax (post exposure), and plague [see Indications and Usage (1.7, 1.8, 1.11)]. An increased incidence of adverse reactions compared to controls, including reactions related to joints and/or surrounding tissues, has been observed [see Adverse Reactions (6.1)].
In pre-clinical studies, oral administration of CIPRO caused lameness in immature dogs. Histopathological examination of the weight-bearing joints of these dogs revealed permanent lesions of the cartilage. Related quinolone-class drugs also produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species [see Use in Specific Populations (8.4) and Nonclinical Toxicology (13.2)].
5.14 Photosensitivity/Phototoxicity
5.14 Photosensitivity/Phototoxicity Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (for example, burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, “V” area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolones including CIPRO after sun or UV light exposure. Therefore, avoid excessive exposure to these sources of light.
Discontinue CIPRO if phototoxicity occurs [see Adverse Reactions (6.1)].
5.15 Development of Drug Resistant Bacteria Prescribing
5.15 Development of Drug Resistant Bacteria Prescribing CIPRO Tablets and CIPRO Oral Suspension in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
5.16 Potential Risks with Concomitant Use of Drugs Metabolized by Cytochrome P450 1
5.16 Potential Risks with Concomitant Use of Drugs Metabolized by Cytochrome P450 1A2 Enzymes CIPRO is an inhibitor of the hepatic CYP1A2 enzyme pathway. Co-administration of CIPRO and other drugs primarily metabolized by CYP1A2 (for example, theophylline, methylxanthines, caffeine, tizanidine, ropinirole, clozapine, olanzapine and zolpidem), results in increased plasma concentrations of the co-administered drug and could lead to clinically significant pharmacodynamic adverse reactions of the co-administered drug [see Drug Interactions (7) and Clinical Pharmacology (12.3)].
5.17 Interference with Timely Diagnosis of Syphilis
5.17 Interference with Timely Diagnosis of Syphilis CIPRO has not been shown to be effective in the treatment of syphilis. Antimicrobial agents used in high dose for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. Perform a serologic test for syphilis in all patients with gonorrhea at the time of diagnosis.
Perform follow-up serologic test for syphilis three months after CIPRO treatment.
5.18 Crystalluria
5.18 Crystalluria Crystals of ciprofloxacin have been observed rarely in the urine of human subjects but more frequently in the urine of laboratory animals, which is usually alkaline [see Nonclinical Toxicology (13.2)]. Crystalluria related to CIPRO has been reported only rarely in humans because human urine is usually acidic.
Avoid alkalinity of the urine in patients receiving CIPRO. Hydrate patients well to prevent the formation of highly concentrated urine [see Dosage and Administration (2.4)].
5.19 Blood Glucose Disturbances
5.19 Blood Glucose Disturbances Fluoroquinolones, including CIPRO, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (for example, glyburide) or with insulin. In these patients, careful monitoring of blood glucose is recommended.
Severe cases of hypoglycemia resulting in coma or death have been reported. If a hypoglycemic reaction occurs in a patient being treated with CIPRO, discontinue CIPRO and initiate appropriate therapy immediately [see Adverse Reactions (6.1), Drug Interactions (7)].
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Tizanidine | Avoid | Potentiated hypotensive and sedative effects. | Contraindicated. |
| Theophylline | Avoid | Higher, prolonged theophylline levels; serious and fatal reactions. | Avoid; if unavoidable, monitor theophylline levels and adjust. |
| QT-prolonging drugs (class IA/III antiarrhythmics, tricyclics, macrolides, antipsychotics) | Avoid | Additive QT prolongation. | Avoid use. |
| Multivalent cations: Mg/Al antacids, sevelamer, lanthanum, sucralfate, calcium, iron, zinc, dairy | Adjust or monitor | Lower ciprofloxacin absorption. | Give ciprofloxacin at least 2 hours before or 6 hours after these products. |
| Oral antidiabetic drugs (mainly sulfonylureas) | Adjust or monitor | Severe hypoglycemia, including fatalities. | Monitor blood glucose. |
| Warfarin and oral anticoagulants | Adjust or monitor | Increased anticoagulant effect. | Monitor PT/INR often during and shortly after. |
| Cyclosporine | Adjust or monitor | Transient rises in serum creatinine. | Monitor kidney function (serum creatinine). |
| Methotrexate | Adjust or monitor | Less renal tubular transport; higher methotrexate levels and toxicity. | Monitor closely. |
| Probenecid | Adjust or monitor | About 50% lower ciprofloxacin renal clearance; higher levels. | Use with caution. |
| Duloxetine, zolpidem | Avoid | Duloxetine exposure about 5-fold; higher zolpidem levels. | Avoid use. |
| NSAIDs (not aspirin) | Adjust or monitor | Convulsions with very high quinolone doses. | Use with caution. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
7 DRUG INTERACTIONS Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of CIPRO with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug.
Table 11: Drugs That are Affected by and Affecting CIPRO Drugs That are Affected by CIPRO Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and CIPRO is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications (4.2)] Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) Concurrent administration of CIPRO with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate [see Warnings and Precautions (5.10)].
Drugs Known to Prolong QT Interval Avoid Use CIPRO may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) [see Warnings and Precautions (5.12) and Use in Specific Populations (8.5)]. Oral antidiabetic drugs Use with caution Glucose-lowering effect potentiated Hypoglycemia sometimes severe has been reported when CIPRO and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent.
Fatalities have been reported. Monitor blood glucose when CIPRO is co-administered with oral antidiabetic drugs [see Adverse Reactions (6.1)]. Phenytoin Use with caution Altered serum levels of phenytoin (increased and decreased) To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon CIPRO discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of CIPRO with phenytoin.
Cyclosporine Use with caution (transient elevations in serum creatinine) Monitor renal function (in particular serum creatinine) when CIPRO is co-administered with cyclosporine. Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of CIPRO to the increase in INR (international normalized ratio) is difficult to assess.
Monitor prothrombin time and INR frequently during and shortly after co-administration of CIPRO with an oral anti-coagulant (for example, warfarin). Methotrexate Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels Potential increase in the risk of methotrexate associated toxic reactions.
Therefore, carefully monitor patients under methotrexate therapy when concomitant CIPRO therapy is indicated. Ropinirole Use with caution Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with CIPRO [see Warnings and Precautions (5.16)].
Clozapine Use with caution Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with CIPRO are advised. NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.
Sildenafil Use with caution Two-fold increase in exposure Monitor for sildenafil toxicity [see Clinical Pharmacology (12.3)]. Duloxetine Avoid Use Five-fold increase in duloxetine exposure If unavoidable, monitor for duloxetine toxicity Caffeine/Xanthine Derivatives Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life CIPRO inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products).
Monitor for xanthine toxicity and adjust dose as necessary. Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended Drug(s) Affecting Pharmacokinetics of CIPRO Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx ® (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) CIPRO should be taken at least two hours before or six hours after Multivalent cation-containing products administration [see Dosage and Administration (2.4)].
Decrease CIPRO absorption, resulting in lower serum and urine levels Probenecid Use with caution (interferes with renal tubular secretion of CIPRO and increases CIPRO serum levels) Potentiation of CIPRO toxicity may occur. Interacting Drug Interaction Theophylline Serious and fatal reactions. Avoid concomitant use. Monitor serum level (7) Warfarin Anticoagulant effect enhanced.
Monitor prothrombin time, INR, and bleeding (7) Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. Monitor blood glucose (7) Phenytoin Monitor phenytoin level (7) Methotrexate Monitor for methotrexate toxicity (7) Cyclosporine May increase serum creatinine. Monitor serum creatinine (7) Multivalent cation-containing products including antacids, metal cations or didanosine Decreased CIPRO absorption.
Take CIPRO 2 hours before or 6 hours after administration of multivalent cation containing drugs (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism.
Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug [see Contraindications ( 4.2 ), Warnings and Precautions ( 5.10 , 5.16 ), and Drug Interactions ( 7 )].
Duloxetine In clinical studies it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in a 5-fold increase in mean AUC and a 2.5-fold increase in mean C max of duloxetine.
7 DRUG INTERACTIONS Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism.
Co-administration of CIPRO with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug.
Adverse reactions
Common
- Nausea, diarrhea, abnormal liver tests, vomiting, rash (most common, ≥1%)
Serious
- Tendinitis and tendon rupture (boxed warning)
- Peripheral neuropathy (boxed warning)
- Central nervous system effects (boxed warning)
- Exacerbation of myasthenia gravis (boxed warning)
- Hypersensitivity and other serious, sometimes fatal reactions
- Hepatotoxicity
- Aortic aneurysm and dissection
- Clostridioides difficile-associated diarrhea
- QT prolongation
- Blood glucose disturbances
- Crystalluria (rare)
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling:
- Disabling and Potentially Irreversible Serious Adverse Reactions [see Warnings and Precautions (5.1)]
- Tendinitis and Tendon Rupture [see Warnings and Precautions (5.2)]
- Peripheral Neuropathy [see Warnings and Precautions (5.3)]
- Central Nervous System Effects [see Warnings and Precautions (5.4)] Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5.5)]
- Other Serious and Sometimes Fatal Adverse Reactions [see Warnings and Precautions (5.6)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.7)]
- Hepatotoxicity [see Warnings and Precautions (5.8)]
- Risk of Aortic Aneurysm and Dissection [see Warnings and Precautions (5.9)]
- Serious Adverse Reactions with Concomitant Theophylline [see Warnings and Precautions (5.10)]
- Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.11)]
- Prolongation of the QT Interval [see Warnings and Precautions (5.12)]
- Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5.13)]
- Photosensitivity/Phototoxicity [see Warnings and Precautions (5.14)]
- Development of Drug Resistant Bacteria [see Warnings and Precautions (5.15)] The most common adverse reactions ≥1% were nausea, diarrhea, liver function tests …
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients During clinical investigations with oral and parenteral CIPRO, 49,038 patients received courses of the drug.
The most frequently reported adverse reactions, from clinical trials of all formulations, all dosages, all drug-therapy durations, and for all indications of ciprofloxacin therapy were nausea (2.5%), diarrhea (1.6%), liver function tests abnormal (1.3%), vomiting (1%), and rash (1%). Table 8: Medically Important Adverse Reactions That Occurred In less than 1% of Ciprofloxacin Patients System Organ Class Adverse Reactions Body as a Whole Headache Abdominal Pain/Discomfort Pain Cardiovascular Syncope Angina Pectoris Myocardial Infarction Cardiopulmonary Arrest Tachycardia Hypotension Central Nervous System Restlessness Dizziness Insomnia Nightmares Hallucinations Paranoia Psychosis (toxic) Manic Reaction Irritability Tremor Ataxia Seizures (including Status Epilepticus) Malaise Anorexia Phobia Depersonalization Depression (potentially culminating in self-injurious behavior (such as suicidal ideations/thoughts and attempted or completed suicide) Paresthesia Abnormal Gait Migraine Gastrointestinal Intestinal Perforation Gastrointestinal Bleeding Cholestatic Jaundice Hepatitis Pancreatitis Hemic/Lymphatic Petechia Metabolic/Nutritional Hyperglycemia Hypoglycemia Musculoskeletal Arthralgia Joint Stiffness Muscle Weakness Renal/Urogenital Interstitial Nephritis Renal Failure Respiratory Dyspnea Laryngeal Edema Hemoptysis Bronchospasm Skin/Hypersensitivity Anaphylactic Reactions including life-threatening anaphylactic shock Erythema Multiforme/Stevens-Johnson Syndrome Exfoliative Dermatitis Toxic Epidermal Necrolysis Pruritus Urticaria Photosensitivity/Phototoxicity reaction Flushing Fever Angioedema Erythema Nodosum Sweating Special Senses Blurred Vision Disturbed Vision (chromatopsia and photopsia) Decreased Visual Acuity Diplopia Tinnitus Hearing Loss Bad Taste In randomized, double-blind controlled clinical trials comparing CIPRO tablets [500 mg two times daily (BID)] to cefuroxime axetil (250 mg–500 mg BID) and to clarithromycin (500 mg BID) in patients with respiratory tract infections, CIPRO demonstrated a CNS adverse reaction profile comparable to the control drugs.
Pediatric Patients Short (6 weeks) and long term (1 year) musculoskeletal and neurological safety of oral/intravenous ciprofloxacin, was compared to a cephalosporin for treatment of cUTI or pyelonephritis in pediatric patients 1 to 17 years of age (mean age of 6 ± 4 years) in an international multicenter trial. The duration of therapy was 10 to 21 days (mean duration of treatment was 11 days with a range of 1 to 88 days).
A total of 335 ciprofloxacin- and 349 comparator-treated patients were enrolled. An Independent Pediatric Safety Committee (IPSC) reviewed all cases of musculoskeletal adverse reactions including abnormal gait or abnormal joint exam (baseline or treatment-emergent). Within 6 weeks of treatment initiation, the rates of musculoskeletal adverse reactions were 9.3% (31/335) in the ciprofloxacin-treated group versus 6% (21/349) in comparator-treated patients.
All musculoskeletal adverse reactions occurring by 6 weeks resolved (clinical resolution of signs and symptoms), usually within 30 days of end of treatment. Radiological evaluations were not routinely used to confirm resolution of the adverse reactions. Ciprofloxacin-treated patients were more likely to report more than one adverse reaction and on more than one occasion compared to control patients.
The rate of musculoskeletal adverse reactions was consistently higher in the ciprofloxacin group compared to the control group across all age subgroups. At the end of 1 year, the rate of these adverse reactions reported at any time during that period was 13.7% (46/335) in the ciprofloxacin-treated group versus 9.5% (33/349) in the comparator-treated patients (Table 9).
Table 9: Musculoskeletal Adverse Reactions Included: arthralgia, abnormal gait, abnormal joint exam, joint sprains, leg pain, back pain, arthrosis, bone pain, pain, myalgia, arm pain, and decreased range of motion in a joint (knee, elbow, ankle, hip, wrist, and shoulder) as Assessed by the IPSC CIPRO Comparator All Patients (within 6 weeks) 31/335 (9.3%) 21/349 (6%) 95% Confidence Interval The study was designed to demonstrate that the arthropathy rate for the ciprofloxacin group did not exceed that of the control group by more than + 6%. At both the 6 week and 1 year evaluations, the 95% confidence interval indicated that it could not be concluded that the ciprofloxacin group had findings comparable to the control group.
(-0.8%, +7.2%) Age Group 12 months < 24 months 1/36 (2.8%) 0/41 2 years < 6 years 5/124 (4%) 3/118 (2.5%) 6 years < 12 years 18/143 (12.6%) 12/153 (7.8%) 12 years to 17 years 7/32 (21.9%) 6/37 (16.2 %) All Patients (within 1 year) 46/335 (13.7%) 33/349 (9.5%) 95% Confidence Interval (-0.6%, + 9.1%) The incidence rates of neurological adverse reactions within 6 weeks of treatment initiation were 3% (9/335) in the CIPRO group versus 2% (7/349) in the comparator group and included dizziness, nervousness, insomnia, and somnolence. In this trial, the overall incidence rates of adverse reactions within 6 weeks of treatment initiation were 41% (138/335) in the ciprofloxacin group versus 31% (109/349) in the comparator group.
The most frequent adverse reactions were gastrointestinal: 15% (50/335) of ciprofloxacin patients compared to 9% (31/349) of comparator patients. Serious adverse reactions were seen in 7.5% (25/335) of ciprofloxacin-treated patients compared to 5.7% (20/349) of control patients. Discontinuation of drug due to an adverse reaction was observed in 3% (10/335) of ciprofloxacin-treated patients versus 1.4% (5/349) of comparator patients.
Other adverse reactions that occurred in at least 1% of ciprofloxacin patients were diarrhea 4.8%, vomiting 4.8%, abdominal pain 3.3%, dyspepsia 2.7%, nausea 2.7%, fever 2.1%, asthma 1.8% and rash 1.8%. Short-term safety data for ciprofloxacin was also collected in a randomized, double-blind clinical trial for the treatment of acute pulmonary exacerbations in cystic fibrosis patients (ages 5–17 years).
Sixty seven patients received CIPRO IV 10 mg/kg/dose every 8 hours for one week followed by CIPRO tablets 20 mg/kg/dose every 12 hours to complete 10–21 days treatment and 62 patients received the combination of ceftazidime intravenous 50 mg/kg/dose every 8 hours and tobramycin intravenous 3 mg/kg/dose every 8 hours for a total of 10–21 days. Periodic musculoskeletal assessments were conducted by treatment-blinded examiners.
Patients were followed for an average of 23 days after completing treatment (range 0–93 days). Musculoskeletal adverse reactions were reported in 22% of the patients in the ciprofloxacin group and 21% in the comparison group. Decreased range of motion was reported in 12% of the subjects in the ciprofloxacin group and 16% in the comparison group.
Arthralgia was reported in 10% of the patients in the ciprofloxacin group and 11% in the comparison group. Other adverse reactions were similar in nature and frequency between treatment arms. The efficacy of CIPRO for the treatment of acute pulmonary exacerbations in pediatric cystic fibrosis patients has not been established.
In addition to the adverse reactions reported in pediatric patients in clinical trials, it should be expected that adverse reactions reported in adults during clinical trials or postmarketing experience may also occur in pediatric patients.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been reported from worldwide marketing experience with fluoroquinolones, including CIPRO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure (Table 10).
Table 10: Postmarketing Reports of Adverse Drug Reactions System Organ Class Adverse Reactions Cardiovascular QT prolongation Torsade de Pointes Vasculitis and ventricular arrhythmia Acute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction Central Nervous System Hypertonia Myasthenia Exacerbation of myasthenia gravis Peripheral neuropathy Polyneuropathy Twitching Eye Disorders Nystagmus Gastrointestinal Pseudomembranous colitis Hemic/Lymphatic Pancytopenia (life threatening or fatal outcome) Methemoglobinemia Hepatobiliary Hepatic failure (including fatal cases) Infections and Infestations Candidiasis (oral, gastrointestinal, vaginal) Investigations Prothrombin time prolongation or decrease Cholesterol elevation (serum) Potassium elevation (serum) Musculoskeletal Myalgia Myoclonus Tendinitis Tendon rupture Psychiatric Disorders Agitation Confusion Delirium Skin/Hypersensitivity Acute generalize exanthematous pustulosis (AGEP) Fixed eruption Serum sickness-like reaction Special Senses Anosmia Hyperesthesia Hypesthesia Taste loss
6.3 Adverse Laboratory Changes
6.3 Adverse Laboratory Changes Changes in laboratory parameters while on CIPRO are listed below: Hepatic –Elevations of ALT (SGPT), AST (SGOT), alkaline phosphatase, LDH, serum bilirubin. Hematologic–Eosinophilia, leukopenia, decreased blood platelets, elevated blood platelets, pancytopenia. Renal–Elevations of serum creatinine, BUN, crystalluria, cylindruria, and hematuria have been reported.
Other changes occurring were: elevation of serum gammaglutamyl transferase, elevation of serum amylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, anemia, bleeding diathesis, increase in blood monocytes, and leukocytosis.
Adverse reaction frequency tables (US label) US FDA label
| System Organ Class | Adverse Reactions |
|---|---|
| Body as a Whole | HeadacheAbdominal Pain/DiscomfortPain |
| Cardiovascular | SyncopeAngina PectorisMyocardial InfarctionCardiopulmonary ArrestTachycardiaHypotension |
| Central Nervous System | RestlessnessDizziness Insomnia NightmaresHallucinations ParanoiaPsychosis (toxic)Manic ReactionIrritabilityTremorAtaxiaSeizures (including Status Epilepticus)MalaiseAnorexiaPhobiaDepersonalizationDepression (potentially culminating in self-injurious behavior(such as suicidal ideations/thoughts and attempted or completed suicide) ParesthesiaAbnormal GaitMigraine |
| Gastrointestinal | Intestinal PerforationGastrointestinal BleedingCholestatic JaundiceHepatitisPancreatitis |
| Hemic/Lymphatic | Petechia |
| Metabolic/Nutritional | HyperglycemiaHypoglycemia |
| Musculoskeletal | ArthralgiaJoint StiffnessMuscle Weakness |
| Renal/Urogenital | Interstitial NephritisRenal Failure |
| Respiratory | Dyspnea Laryngeal EdemaHemoptysisBronchospasm |
| Skin/Hypersensitivity | Anaphylactic Reactions including life-threatening anaphylactic shockErythema Multiforme/Stevens-Johnson SyndromeExfoliative DermatitisToxic Epidermal NecrolysisPruritusUrticariaPhotosensitivity/Phototoxicity reactionFlushingFeverAngioedemaErythema NodosumSweating |
| Special Senses | Blurred VisionDisturbed Vision (chromatopsia and photopsia)Decreased Visual AcuityDiplopiaTinnitusHearing LossBad Taste |
| System Organ Class | Adverse Reactions |
| Cardiovascular | QT prolongationTorsade de PointesVasculitis and ventricular arrhythmiaAcute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction |
| Central Nervous System | HypertoniaMyastheniaExacerbation of myasthenia gravisPeripheral neuropathyPolyneuropathyTwitching |
| Eye Disorders | Nystagmus |
| Gastrointestinal | Pseudomembranous colitis |
| Hemic/Lymphatic | Pancytopenia (life threatening or fatal outcome)Methemoglobinemia |
| Hepatobiliary | Hepatic failure (including fatal cases) |
| Infections and Infestations | Candidiasis (oral, gastrointestinal, vaginal) |
| Investigations | Prothrombin time prolongation or decreaseCholesterol elevation (serum)Potassium elevation (serum) |
| Musculoskeletal | MyalgiaMyoclonusTendinitisTendon rupture |
| Psychiatric Disorders | Agitation ConfusionDelirium |
| Skin/Hypersensitivity | Acute generalize exanthematous pustulosis (AGEP)Fixed eruptionSerum sickness-like reaction |
| Special Senses | AnosmiaHyperesthesiaHypesthesiaTaste loss |
Monitoring parameters
- Tendon rupture, QT prolongation, dysglycemia, central nervous system effects; crystalluria (keep hydrated). Kidney
- Kidney function for dose selection
- Blood glucose in patients on antidiabetic drugs
- PT/INR with warfarin
- Tendon pain, neuropathy and mental status changes
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Prolonged experience with ciprofloxacin in pregnant women over several decades, based on available published information from case reports, case control studies and observational studies on ciprofloxacin administered during pregnancy, have not identified any drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes (see Data). Oral administration of ciprofloxacin during organogenesis at doses up to 100 mg/kg to pregnant mice and rats, and up to 30 mg/kg to pregnant rabbits did not cause fetal malformations (see Data).
These doses were up to 0.3, 0.6, and 0.4 times the maximum recommended clinical oral dose in mice, rats, and rabbits, respectively, based on body surface area. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from prospective observational studies over several decades have not established an association with ciprofloxacin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Available studies have methodological limitations including small sample size and some of them are not specific for ciprofloxacin. A controlled prospective observational study followed 200 women exposed to fluoroquinolones (52.5% exposed to ciprofloxacin and 68% first trimester exposures) during gestation. In utero exposure to fluoroquinolones during embryogenesis was not associated with increased risk of major malformations.
The reported rates of major congenital malformations were 2.2% for the fluoroquinolone group and 2.6% for the control group (background incidence of major malformations is 1–5%). Rates of spontaneous abortions, prematurity and low birth weight did not differ between the groups and there were no clinically significant musculoskeletal dysfunctions up to one year of age in the ciprofloxacin exposed children.
Another prospective follow-up study reported on 549 pregnancies with fluoroquinolone exposure (93% first trimester exposures). There were 70 ciprofloxacin exposures, all within the first trimester. The malformation rates among live-born babies exposed to ciprofloxacin and to fluoroquinolones overall were both within background incidence ranges.
No specific patterns of congenital abnormalities were found. The study did not reveal any clear adverse reactions due to in utero exposure to ciprofloxacin. No differences in the rates of prematurity, spontaneous abortions, or birth weight were seen in women exposed to ciprofloxacin during pregnancy. However, these small postmarketing epidemiology studies, of which most experience is from short term, first trimester exposure, are insufficient to evaluate the risk for less common defects or to permit reliable and definitive conclusions regarding the safety of ciprofloxacin in pregnant women and their developing fetuses.
Animal Data Developmental toxicology studies have been performed with ciprofloxacin in rats, mice, and rabbits. In rats and mice, oral doses up to 100 mg/kg administered during organogenesis (Gestation Days, GD, 6-17) were not associated with adverse developmental outcomes, including embryofetal toxicity or malformations.
In rats and mice, a 100 mg/kg dose is approximately 0.6 and 0.3 times the maximum daily human oral dose (1500 mg/day) based upon body surface area, respectively. In a series of rabbit developmental toxicology studies, does received oral or intravenous ciprofloxacin for one of the following 5 day periods: GD 6 to 10, GD 10 to 14, or GD 14 to 18, intended to cover the period of organogenesis.
This was an attempt to mitigate the gastrointestinal intolerance observed in rabbits that receive antibacterials manifested by reduced maternal food consumption and weight loss, that can lead to embryofetal resorption or spontaneous abortion. An oral ciprofloxacin dose of 100 mg/kg (approximately 1.3 times the highest recommended clinical oral dose based on body surface area) caused excessive maternal toxicity confounding evaluation of the fetuses.
A 30 mg/kg oral dose (approximately 0.4 times the highest recommended clinical oral dose) was associated with suppression of maternal and fetal body weight gain, but fetal malformations were not observed. Intravenous administration of doses up to 20 mg/kg (approximately 0.3 times the highest recommended clinical oral dose based upon body surface area) to pregnant rabbits was not maternally toxic and neither embryofetal toxicity nor fetal malformations were observed.
In peri- and post-natal studies, rats received ciprofloxacin doses up to 200 mg/kg/day (oral) or up to 30 mg/kg/day (subcutaneous) from GD 16 to 22 days postpartum. The 200 mg/kg dose is approximately 1.3-times the maximum recommended clinical oral dose based on body surface area. Neither maternal toxicity nor adverse effects on growth and development of the pups were observed, including no sign of arthropathy on the rear leg joints of the pups.
Ciprofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested when administered directly [see Warnings and Precautions (5.13) and Nonclinical Toxicology 13.2].
Mechanism of action
12.1 Mechanism of Action Ciprofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12.4)].
Mechanism of Action The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.
US FDA labelPharmacokinetics
Key PK parameters
| Bioavailability | About 70% (tablet) |
|---|---|
| Time to peak | About 1 hour (about 2 hours with food, tablet) |
| Half-life | About 4 hours (normal kidney function) |
| Half-life in kidney failure (ESKD) kidney | Slightly prolonged in reduced kidney function (label; no ESKD value given) |
| Protein binding | 20% to 40% |
| Metabolism (CYP, transporters) | Four urinary metabolites (about 15% of an oral dose), less active than parent; CYP1A2 inhibitor |
| Active metabolites | Yes, but less active than ciprofloxacin |
| Dialyzability kidney | Minimal: less than 10% removed by hemodialysis or peritoneal dialysis (label). |
The serum elimination half-life in subjects with normal renal function is approximately 4 hours.
Excretion The serum elimination half-life in subjects with normal renal function is approximately 4 hours.
Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug.
The urinary excretion of ciprofloxacin is virtually complete within 24 hours after dosing.
The renal clearance of ciprofloxacin, which is approximately 300 mL/minute, exceeds the normal glomerular filtration rate of 120 mL/minute.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption The absolute bioavailability of ciprofloxacin when given as an oral tablet is approximately 70% with no substantial loss by first pass metabolism. Ciprofloxacin maximum serum concentrations (C max) and area under the curve (AUC) are shown in the chart for the 250 mg to 1000 mg dose range (Table 12).
Table 12: Ciprofloxacin C max and AUC Following Administration of Single Doses of CIPRO Tablets to Healthy Subjects Dose (mg) C max (mcg/mL) AUC (mcg•hr/mL) 250 1.2 4.8 500 2.4 11.6 750 4.3 20.2 1000 5.4 30.8 Maximum serum concentrations are attained 1 to 2 hours after oral dosing. Mean concentrations 12 hours after dosing with 250, 500, or 750 mg are 0.1, 0.2, and 0.4 mcg/mL, respectively.
The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Serum concentrations increase proportionately with doses up to 1000 mg. A 500 mg oral dose given every 12 hours has been shown to produce an AUC equivalent to that produced by an intravenous infusion of 400 mg CIPRO given over 60 minutes every 12 hours.
A 750 mg oral dose given every 12 hours has been shown to produce an AUC at steady-state equivalent to that produced by an intravenous infusion of 400 mg given over 60 minutes every 8 hours. A 750 mg oral dose results in a C max similar to that observed with a 400 mg intravenous dose (Table 13). A 250 mg oral dose given every 12 hours produces an AUC equivalent to that produced by an infusion of 200 mg CIPRO given every 12 hours.
Table 13: Steady-state Pharmacokinetic Parameters Following Multiple Oral and Intravenous Doses (Adults) Parameters 500 mg 400 mg 750 mg 400 mg every 12 hours, orally every 12 hours, intravenously every 12 hours, orally every 8 hours, intravenously AUC 0-24h,ss (µg•h/mL) 27.4 AUC 0-12h x 2 25.4 31.6 32.9 AUC 0-8h x 3 C max, ss (µg/mL) 2.97 4.56 3.59 4.07 Food When CIPRO Tablet is given concomitantly with food, there is a delay in the absorption of the drug, resulting in peak concentrations that occur closer to 2 hours after dosing rather than 1 hour whereas there is no delay observed when CIPRO Suspension is given with food. The overall absorption of CIPRO Tablet or CIPRO Suspension, however, is not substantially affected.
The pharmacokinetics of ciprofloxacin given as the suspension are also not affected by food. Avoid concomitant administration of CIPRO with dairy products (like milk or yogurt) or calcium-fortified juices alone since decreased absorption is possible; however, CIPRO may be taken with a meal that contains these products With oral administration, a 500 mg dose, given as 10 mL of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to the 500 mg tablet.
A 10 mL volume of the 5% CIPRO Suspension (containing 250 mg ciprofloxacin/5mL) is bioequivalent to a 5 mL volume of the 10% CIPRO Suspension (containing 500 mg ciprofloxacin/5mL). Distribution The binding of ciprofloxacin to serum proteins is 20% to 40% which is not likely to be high enough to cause significant protein binding interactions with other drugs.
After oral administration, ciprofloxacin is widely distributed throughout the body. Tissue concentrations often exceed serum concentrations in both men and women, particularly in genital tissue including the prostate. Ciprofloxacin is present in active form in the saliva, nasal and bronchial secretions, mucosa of the sinuses, sputum, skin blister fluid, lymph, peritoneal fluid, bile, and prostatic secretions.
Ciprofloxacin has also been detected in lung, skin, fat, muscle, cartilage, and bone. The drug diffuses into the cerebrospinal fluid (CSF); however, CSF concentrations are generally less than 10% of peak serum concentrations. Low levels of the drug have been detected in the aqueous and vitreous humors of the eye. Metabolism Four metabolites have been identified in human urine which together account for approximately 15% of an oral dose.
The metabolites have antimicrobial activity, but are less active than unchanged ciprofloxacin. Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug [see Contraindications (4.2), Warnings and Precautions (5.10, 5.16), and Drug Interactions (7)].
Excretion The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. After a 250 mg oral dose, urine concentrations of ciprofloxacin usually exceed 200 mcg/mL during the first two hours and are approximately 30 mcg/mL at 8 to 12 hours after dosing.
The urinary excretion of ciprofloxacin is virtually complete within 24 hours after dosing. The renal clearance of ciprofloxacin, which is approximately 300 mL/minute, exceeds the normal glomerular filtration rate of 120 mL/minute. Thus, active tubular secretion would seem to play a significant role in its elimination. Co-administration of probenecid with ciprofloxacin results in about a 50% reduction in the ciprofloxacin renal clearance and a 50% increase in its concentration in the systemic circulation.
Although bile concentrations of ciprofloxacin are several fold higher than serum concentrations after oral dosing, only a small amount of the dose administered is recovered from the bile as unchanged drug. An additional 1% to 2% of the dose is recovered from the bile in the form of metabolites. Approximately 20% to 35% of an oral dose is recovered from the feces within 5 days after dosing.
This may arise from either biliary clearance or transintestinal elimination. Specific Populations Elderly Pharmacokinetic studies of the oral (single dose) and intravenous (single and multiple dose) forms of ciprofloxacin indicate that plasma concentrations of ciprofloxacin are higher in elderly subjects (older than 65 years) as compared to young adults.
Although the C max is increased 16% to 40%, the increase in mean AUC is approximately 30%, and can be at least partially attributed to decreased renal clearance in the elderly. Elimination half-life is only slightly (~20%) prolonged in the elderly. These differences are not considered clinically significant [see Use in Specific Populations (8.5)].
Renal Impairment In patients with reduced renal function, the half-life of ciprofloxacin is slightly prolonged. Dosage adjustments may be required [see Use in Specific Populations (8.6) and Dosage and Administration (2.3)]. Hepatic Impairment In preliminary studies in patients with stable chronic liver cirrhosis, no significant changes in ciprofloxacin pharmacokinetics have been observed.
The kinetics of ciprofloxacin in patients with acute hepatic insufficiency, have not been fully studied. Pediatrics Table 14 summarizes pharmacokinetic parameters in pediatric patients aged less than 1 to less than 12 years of age receiving intravenous treatment. Table 14: Estimated AUC 0–24,ss and C max,ss for Intravenous Treatment (1-h infusion) in Pediatric Patients Following a Multiple Dosing Regimen of 10 mg/kg, Three Times Daily Age AUC0–24,ss (mg h/L) Cmax,ss (mg/L) Less than1 year 30.9 3 x AUC0–8,ss 2.8 1 to less than 2 years 27.8 3.6 2 to less than 6 years 28.9 2.7 6 to less than 12 years 20.4 2.0 These values are within the range reported for adults at therapeutic doses.
Based on population pharmacokinetic analysis of pediatric patients with various infections, the predicted mean half-life in children is approximately 4 hours –5 hours, and the bioavailability of the oral suspension is approximately 60%. Drug-Drug Interactions Antacids Concurrent administration of antacids containing magnesium hydroxide or aluminum hydroxide may reduce the bioavailability of ciprofloxacin by as much as 90% [see Dosage and Administration (2.4) and Drug Interactions (7)].
Histamine H2-receptor antagonists Histamine H 2 -receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin. Metronidazole The serum concentrations of ciprofloxacin and metronidazole were not altered when these two drugs were given concomitantly. Tizanidine In a pharmacokinetic study, systemic exposure of tizanidine (4 mg single dose) was significantly increased (C max 7-fold, AUC 10-fold) when the drug was given concomitantly with CIPRO (500 mg twice a day for 3 days).
Concomitant administration of tizanidine and CIPRO is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications (4.2)]. Ropinirole In a study conducted in 12 patients with Parkinson’s disease who were administered 6 mg ropinirole once daily with 500 mg CIPRO twice-daily, the mean C max and mean AUC of ropinirole were increased by 60% and 84%, respectively.
Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with CIPRO [see Warnings and Precautions (5.10)]. Clozapine Following concomitant administration of 250 mg CIPRO with 304 mg clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively.
Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with CIPRO are advised. Sildenafil Following concomitant administration of a single oral dose of 50 mg sildenafil with 500 mg CIPRO to healthy subjects, the mean C max and mean AUC of sildenafil were both increased approximately two-fold.
Use sildenafil with caution when co-administered with CIPRO due to the expected two-fold increase in the exposure of sildenafil upon co-administration of CIPRO. Duloxetine In clinical studies it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in a 5-fold increase in mean AUC and a 2.5-fold increase in mean C max of duloxetine.
Lidocaine In a study conducted in 9 healthy volunteers, concomitant use of 1.5 mg/kg IV lidocaine with CIPRO 500 mg twice daily resulted in an increase of lidocaine C max and AUC by 12% and 26%, respectively. Although lidocaine treatment was well tolerated at this elevated exposure, a possible interaction with CIPRO and an increase in adverse reactions related to lidocaine may occur upon concomitant administration.
Metoclopramide Metoclopramide significantly accelerates the absorption of oral ciprofloxacin resulting in a shorter time to reach maximum plasma concentrations. No significant effect was observed on the bioavailability of ciprofloxacin. Omeprazole When CIPRO was administered as a single 1000 mg dose concomitantly with omeprazole (40 mg once daily for three days) to 18 healthy volunteers, the mean AUC and C max of ciprofloxacin were reduced by 20% and 23%, respectively.
The clinical significance of this interaction has not been determined.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ciprofloxacin 2 mg/mL, 200 mL Vial | ₱65.00–₱1,665.81Reference ₱1,187.00 | per vial | DPRI procurement range |
| Ciprofloxacin 2 mg/mL,100 mL Vial | ₱17.73–₱400.00Reference ₱23.78 | per vial | DPRI procurement range |
| Ciprofloxacin 500 mg Tablet | ₱1.13–₱19.35Reference ₱1.30 | per tablet | DPRI procurement range |
| 250 mg (as hydrochloride) tablet | ₱32.00 | per tablet | PhilHealth GAMOT fixed fee |
| 500 mg (as hydrochloride) tablet | ₱25.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Ciprofloxacin |
| PNF listing | Oral: 250 mg and 500 mg tablet (as hydrochloride) |
| PNF listing | Inj.: 2 mg/mL, 100 mL vial (IV infusion) (as lactate) |
| PNF listing | Inj.: 400 mg/200 mL (IV infusion) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cipro · Bayer HealthCare Pharmaceuticals Inc. [US FDA-approved label, version 32, March 2, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Bayer HealthCare Pharmaceuticals Inc.. (2026). Cipro (ciprofloxacin hydrochloride) [Prescribing information; US FDA-approved label, NDA019537, set ID 888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0, version effective March 2, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=888dc7f9-ad9c-4c00-8d50-8ddfd9bd27c0
- Baxter Healthcare Corporation. (2020). Ciprofloxacin injection (ciprofloxacin) [Prescribing information; US FDA-approved label, set ID e82f52f2-ecf8-4c04-a206-f3253b265903, version effective July 10, 2020]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e82f52f2-ecf8-4c04-a206-f3253b265903
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .


